

Author Index for 1992

- Åsberg, M. 43:161
Adinoff, B. 41:89
Adler, L. 44:21
Allen, E.M. 42:221
Alphs, L. 43:87
Altman, E.S. 41:1
Altshuler, L. 44:79
Amin, F. 43:1
Anderson, D.L. 43:121
Antonozzi, I. 42:159
Apter, S. 43:1, 44:153
Arató, M. 42:189
Arbisi, P.A. 43:147
Armitage, R. 41:65
Asnis, G.M. 43:65, 44:237
Axelson, D.A. 44:63
Babron, M.C. 44:171
Bagby, R.M. 42:73
Baker, G.B. 41:267, 43:277
Baker, N. 44:21
Baker, R. 43:299
Balldin, J. 41:257
Balon, R. 43:253
Banki, C.M. 43:13
Barnas, C. 42:121
Battaglia, M. 41:283
Baxter, L.R., Jr. 42:221
Beattie, C.W. 43:55
Bechter, K. 42:193, 42:291
Beck, A.T. 42:93
Beck, N.C. 43:231
Beglin, S.J. 44:191
Beiser, M. 43:215
Bela, A. 42:189
Bellodi, L. 41:283, 42:111
Berggren, U. 41:257
Berlanga, C. 44:257
Berman, S. 42:81
Bernstein, D. 43:199
Betz, F. 42:93
Bielski, R.J. 43:167
Bienenfeld, D. 41:73
Bierer, L.M. 42:101
Bihari, K. 42:267
Binkert, M. 42:209
Bissette, G. 43:13
Böning, J. 41:227
Boekamp, J. 43:87
Born, J. 44:125
Bornstein, R.A. 41:267, 43:277
Boutros, N.N. 41:249
Bovier, P. 43:243
Bowers, M.B., Jr. 41:147
Boyko, O.B. 44:63
Bracha, H.S. 43:187
Brar, J.S. 44:113
Bridger, W.H. 42:65, 43:263
Brown, G.M. 43:31, 43:177
Brown, W.A. 41:203, 44:9
Buchanan, A. 43:55
Burgess, J.W. 42:283
Buysse, D.J. 42:13, 42:27
Buysse, D.S. 43:43
Caccavari, R. 41:179
Calhoun, J.S. 41:65
Campion, D. 41:99, 41:107, 44:171
Capesciotti, G. 42:159
Carter, C.S. 41:137
Casanova, M.F. 44:79
Caspari, A. 41:227
Cassano, G.B. 42:41
Catapano, F. 44:217
Cavelier, B. 41:99
Chaney, J.M. 43:231
Chapman, H.A. 44:203
Chauchat, J.-H. 44:55
Chen, M.-G. 41:203
Chengappa, K.N.R. 44:113
Chiodera, P. 41:179
Christian, J.C. 43:299
Clay, D.L. 43:231
Clerget-Darpoux, F. 41:99, 44:171
Coccaro, E.F. 43:199
Cohen, R. 41:275
Coiro, V. 41:179
Colbert, K. 43:287
Condello, V. 43:199
Cooper, T.B. 42:185, 43:137, 43:263
Copolov, D.L. 41:17
Corkin, S. 44:167
Coursey, R.D. 41:115
Csernansky, J.G. 41:191, 42:81
Cummings, M.A. 43:121
Czobor, P. 42:129
d'Amato, T. 41:99, 41:107, 44:55, 44:171
Dahl, R.E. 41:53
Dalery, J. 44:55
Darko, D.F. 43:111
Dastoli, C. 42:159
Davidson, M. 41:155, 42:101, 43:1, 44:153
Davis, B.M. 41:155
Davis, J.M. 44:1
Davis, K.L. 41:155, 42:101, 44:153
Deakin, J.F.W. 42:273
Dean, B. 41:17
DeCaria, C.M. 42:185
Del Medico, V.J. 44:33
Delsignore, R. 41:179
Depue, R.A. 43:147
des Lauriers, A. 41:107
Diaferia, G. 42:111
Dierks, T. 41:227, 44:93
Dilsaver, S.C. 44:33
Doraiswamy, P.M. 44:63
Drebing, C. 44:21
Drescher, J.P. 44:251
DuMont, K. 43:1
Dysken, M.W. 41:37
Egan, M.F. 43:187
Ehlers, C.L. 42:13
El-Mallakh, R.S. 43:187
Ellinwood, E.H., Jr. 44:63
Elliott, T.R. 43:231
Eneroth, P. 43:161
Erwin, R.J. 42:231, 42:241, 42:253
Escalona, P.R. 44:63
Evans, D.L. 44:227
Faedda, G.L. 41:215
Fairburn, C.G. 44:191
Feingold, J. 41:107
Ferri, E. 42:159
Filip, V. 41:9
Filteau, M.-J. 41:107
Fleischhacker, W.W. 42:121
Frajese, G. 42:159
Frank, E. 42:13, 42:27
Frank, R.G. 43:231
Frecska, E. 42:189
Freedman, R. 44:21
Friedman, L. 41:25
Friesen, H.G. 41:249
Frölich, L. 44:93
Fuchs, D. 42:121
Fuschino, A. 44:217

- Gabriel, S. 41:155, 43:1
 Gaggiotti, M.T. 41:179
 Gaillard, J.-M. 43:243
 Ganguli, R. 44:113
 Garcia-Borreguero, D. 44:41
 Garvey, M.J. 42:295
 Geider, F.J. 42:209
 Gerhardt, G. 44:21
 Gerra, G. 41:179
 Gilbertson, M.W. 42:53
 Giles, D.E. 41:53
 Gillin, J.C. 43:111
 Gillon, D. 43:137
 Gilmore, G.C. 44:203
 Goldstein, M.J. 41:1
 Goodwin, D.C. 41:215
 Gorwood, P. 41:99, 44:171
 Goswami, U. 42:189
 Grambling, S. 43:231
 Green, M.F. 43:223
 Greil, W. 4:71
 Griffin, M. 41:249
 Growdon, J.H. 44:167
 Grünberger, J. 41:163
 Guilloud-Bataille, M. 41:107
 Gur, R.C. 42:231, 42:241, 42:253
 Gur, R.E. 42:231, 42:241, 42:253
 Gurklis, J.A. 42:53
 Guze, B.H. 42:221
 Háľková, E. 41:9
 Halle, L. 41:99
 Halper, J.P. 42:1
 Hamilton, S. 41:73
 Harvey, P. 43:199, 44:141, 44:153
 Haviland, M.G. 43:121
 Hegerl, U. 44:181
 Heimberg, C. 42:241, 42:253
 Heinrich, H. 44:125
 Heninger, G.R. 43:77
 Herzog, S. 42:193, 42:291
 Hewlett, W.A. 42:81
 Hill, C. 41:17
 Hill, J.L. 42:267
 Hillaire, D. 41:99, 41:107, 44:171
 Hinterhuber, H. 42:121
 Hirschowitz, J. 41:155
 Hoch, C.C. 43:43
 Hollander, E. 42:41, 42:185
 Holsboer, F. 44:41
 Horvath, T.B. 43:199
 Houck, P. 43:23, 41:237
 Hubbard, R.W. 43:121
 Huff, F.J. 44:167
 Husted, J.A. 43:215
 Hwang, S. 41:1
 Iacono, W.G. 43:215
 Ihl, R. 44:93
 Irwin, M.R. 43:111
 Jaeckle, R. 41:45
 Janicak, P.G. 44:1
 Jarrett, D.B. 43:23
 Jatlow, P.I. 41:147
 Jaus, M. 42:209
 Jay, M. 41:99, 41:107, 44:171
 Jesberger, J.A. 41:25
 Joffe, R.T. 42:73
 Johnson, M.F. 41:203
 Joseph, K.C. 43:299
 Kahn, R.S. 41:155, 43:1, 43:65
 Kaplan, C. 41:99
 Karege, F. 43:243
 Karen, P. 41:9
 Karmacs, L. 43:13
 Kathol, R.G. 41:45
 Kay, D.R. 43:231
 Kay, S.R. 42:199
 Keefe, R.S.E. 44:141, 44:153
 Keitner, G.I. 44:9
 Kelley, M.P. 41:115
 Kellner, R. 42:171
 Kemali, D. 44:217
 Kemmler, G. 42:121
 Kennedy, S.H. 43:177
 Kern, R.S. 43:223
 Keshavan, M.S. 43:23
 Kim, S.W. 41:37
 Kindler, S. 43:137
 Kleber, H.D. 43:77
 Kleinman, J.E. 44:79
 Knott, P. 43:199
 Körber, J. 41:227
 Kohn, R. 44:9
 Kojima, T. 43:129
 Koponen, H.J. 44:107
 Korenovsky, A. 43:23
 Kornhuber, H.H. 44:125
 Koshino, Y. 43:129
 Kosten, T.R. 43:77
 Kraemer, H.C. 42:241
 Krauss, S.S. 43:147
 Krieg, J.-C. 44:41
 Krishnan, K.R.R. 44:63
 Kulkarni, J. 41:17
 Kupfer, D.J. 41:53, 42:13, 42:27, 43:43
 Kuskowski, M. 41:37
 Laklou, H. 44:171
 Lam, R.W. 43:55
 Lauer, C.J. 44:41
 Laurent, A. 44:55
 Lawrence, E.K. 43:199
 Lawrence, T.L. 43:199
 Leboyer, M. 41:99, 41:107, 44:171
 Lensi, P. 42:41
 Lenzenweger, M.F. 44:141, 44:153
 Lerer, B. 43:137
 Levitt, A.J. 42:73
 Lichtenberg, P. 43:137
 Liebowitz, M.R. 42:185
 Lindenmayer, J.-P. 42:199
 Lindstedt, G. 41:257
 Lindström, E.M. 42:145
 Lindström, L.H. 42:146
 Linnoila, M. 41:89
 Linzmayer, L. 41:163
 Liukkonen, J. 44:107
 Lohr, J.B. 43:187
 Loimer, N. 41:163
 Lucca, A. 44:85
 Lucini, V. 44:85
 Lycaki, H. 43:253
 Machen, M. 43:43
 MacMurray, J.P. 43:121
 Mador, J.A. 43:55
 Maes, M. 42:295
 Magnani, A. 42:159
 Mahadi, S.P. 43:23
 Mahon, T. 43:199
 Maj, M. 44:217
 Malafosse, A. 44:171
 Mallet, J. 44:171
 Malmgren, R. 43:161
 Malone, V. 41:17
 Mancini, C. 43:31
 Maninetti, L. 41:179
 Marazziti, D. 42:41
 Marie-Cardine, M. 44:55
 Maršálek, M. 41:9
 Martin, E.-M. 44:93
 Martin, K. 42:81
 Mather, J.A. 43:93
 Maurer, K. 44:93
 Mawhinney-Hee, M. 42:231
 Mayerhofer, S. 41:163
 Mayor, J. 43:167
 Mazumdar, S. 41:237
 Mazure, C.M. 41:147

- McBride, R. 43:253
 McDonald, W.M. 44:63
 McDougle, C.J. 43:77
 McGhee, W.H. 43:121
 Mefford, I. 41:89
 Meltzer, H.Y. 41:25, 42:159
 Merskey, H. 43:93
 Miklowitz, D.J. 41:1
 Miller, I.W. 44:9
 Miller, M.D. 41:237
 Mintz, J. 41:1
 Miyasaka, M. 43:129
 Modai, I. 43:161
 Modestin, J. 44:251
 Modigh, K. 41:257
 Mohs, R.C. 42:101, 44:141, 44:153, 44:168
 Monk, T.H. 42:13, 42:27
 Montani, G. 41:179
 Monteleone, P. 44:217
 Moore, C. 41:155
 Mouton, A. 42:53
 Müller-Oerlinghausen, B. 44:181
 Muller, B. 41:99
 Mulsant, B. 41:237
 Murkejee, S. 43:23
 Murphy, D.L. 42:267
 Nakane, Y. 43:129
 Nelson, J.C. 41:147, 43:121
 Nelson, S. 41:73
 Nemeroff, C.B. 43:13, 44:63
 Nerozzi, D. 42:159
 Neufeld, R.W.J. 43:93
 Newcomer, J.W. 41:191
 Newman, M.E. 43:137
 Neylan, T.C. 42:53
 Niedermeier, T. 41:275
 Nordahl, T.E. 41:137
 Norman, W.H. 44:9
 Nousiainen, U. 44:107
 Nurnberger, J.L., Jr. 43:299
 Öhlund, L.S. 42:145
 Öhman, A. 42:145
 Özdaglar, A. 44:41
 O'Connor, D.T. 42:53
 Ontiveros, M. 44:257
 Ortega-Soto, H.A. 44:257
 Osterheider, M. 41:227
 Pakesch, G. 41:163
 Palumbo, D.R. 42:1
 Palumbo, J.M. 43:77
 Pandey, G.N. 44:1
 Paradis, C.F. 41:237
 Pasatiempo, A.P. 42:65, 43:263
 Pasternak, R.E. 43:43
 Pathak, D. 42:171
 Patterson, L.J. 44:63
 Peabody, C.A. 41:249
 Perenyi, A. 42:189
 Peters, J.L. 42:53, 43:287
 Petitto, J.M. 44:227
 Pfersmann, D. 41:163
 Piatti, E. 44:85
 Plutchik, R. 42:199
 Pogge, D.L. 44:141
 Pohl, R. 43:253
 Price, L.H. 43:77
 Qamar, A.B. 44:33
 Quade, D. 44:227
 Rabin, B.S. 44:113
 Rabinovich, H. 42:65, 43:263
 Ramaswamy, G. 41:73
 Ravagli, S. 42:41
 Rea, M.M. 41:1
 Reitz, C. 42:209
 Reynolds, C.F., III 41:237, 43:23, 43:43
 Rice, J. 43:167
 Rifai, A.H. 41:237
 Riney, S.J. 41:191
 Risch, S.C. 43:111
 Ritchie, J.C. 44:63
 Ritenour, A. 42:13, 42:27
 Robertson, L.C. 41:137
 Rochet, T. 44:55
 Roffwarg, H.P. 41:53, 41:65
 Ronchi, P. 42:111, 44:85
 Royston, M.C. 42:273
 Rush, A.J. 41:65
 Russell, N.C. 43:93
 Ryan, C.E. 44:9
 Sabate, O. 44:171
 Sanderson, W.C. 42:93, 43:65, 44:237
 Saoud, J.B. 42:185
 Satz, P. 43:223
 Sauer, H. 42:209
 Schlernitzauer, M. 43:43
 Schmeidler, J. 42:101, 44:153
 Schreiber, H. 44:125
 Schröder, J. 42:209
 Schüttler, R. 42:193, 42:291
 Sciuto, G. 42:111
 Senties, H. 44:257
 Serper, M.R. 44:141
 Shapira, B. 43:137
 Sharma, R.P. 44:1
 Shear, M.K. 42:1
 Sherman, B.M. 41:45
 Shimazono, Y. 43:129
 Shrikanthan, P. 41:17
 Shtasel, D.L. 42:253
 Shutty, M.S. 43:231
 Siever, L.J. 43:1, 43:199
 Silverman, J.M. 42:101
 Simpson, M.D.C. 42:273
 Sinha, D. 41:73
 Sitaram, N. 43:299
 Skolnick, B. 42:231
 Slater, P. 42:273
 Smailis, J. 42:231
 Smeraldi, E. 42:111, 44:85
 Solomon, W. 44:113
 Soufflet, M.F. 41:99
 Sperner-Unterweger, B. 42:121
 Spoont, M. 43:147
 Stack, J.A. 41:237
 Stanley, M. 42:185
 Starcevic, V. 42:171
 Stein, D.J. 42:185
 Steinhauer, S.R. 43:287
 Steller, B. 44:71
 Stern, R.G. 41:155, 42:101, 43:1, 44:168
 Stoff, D.M. 42:65, 43:263
 Stoll, A.L. 41:215
 Stolz-Born, G. 44:125
 Strakowski, S.M. 41:215
 Strauss, M.E. 43:87, 44:203
 Strik, W.K. 41:227
 Suddath, R.L. 43:187
 Sweeney, J.A. 42:1
 Szuba, M.P. 42:221
 Takahashi, R. 43:129
 Terra, J.-L. 44:55
 Thienhaus, O. 41:73
 Tissot, R. 43:243
 Toffler, G. 44:251
 Tohen, M. 41:215
 Trestman, R.L. 43:199
 Trugold, S. 42:185
 Uhlenhuth, E.H. 42:171
 Valevski, A. 43:161
 van Kammen, D.P. 42:53, 43:287
 van Praag, H.M. 43:65, 44:237
 Vinogradov, S. 41:191, 42:81
 Volavka, J. 42:129
 Volpi, R. 41:179
 Wachter, H. 42:121

- Waksman, G. 44:171
Waldo, M. 44:21
Warner, M.D. 41:249
Watzl, H. 41:275
Waxman, R. 41:89
Weinberger, D.R. 44:79
Weiss, K.M. 44:203
Wetterberg, L. 43:161
Wetzler, S. 42:93, 43:65
Widlöcher, D. 41:107
Widmer, J. 43:243
Worsley, I.G. 41:249
Wulff, H. 44:181
Wyatt, R.J. 43:187
Wysham, C. 41:45
Yager, A. 42:221
Yagi, G. 43:129
Yamauchi, T. 43:129
Yang, R.-K. 43:199
Yeragani, V.K. 43:253
Yeung, J. 42:65, 43:263
Zemlan, F.P. 41:73
Zito, M. 44:79
Zubin, J. 43:287
Zwil, A.S. 42:241

Subject Index for 1992

Abnormal movements

dyskinesia, haloperidol, 41:191
dyskinesia, homovanillic acid, 41:191
dyskinesia, negative symptoms, 41:191
dyskinesia, neuroleptics, 41:191
dyskinesia, prolactin, 41:191
dyskinesia, schizophrenia, 41:191
dyskinesia, side effects, 41:191
haloperidol, dyskinesia, 41:191
haloperidol, homovanillic acid, 41:191
haloperidol, negative symptoms, 41:191
haloperidol, prolactin, 41:191
haloperidol, schizophrenia, 41:191
homovanillic acid, dyskinesia, 41:191
homovanillic acid, haloperidol, 41:191
homovanillic acid, negative symptoms, 41:191
homovanillic acid, neuroleptics, 41:191
homovanillic acid, prolactin, 41:191
homovanillic acid, schizophrenia, 41:191
negative symptoms, dyskinesia, 41:191
negative symptoms, haloperidol, 41:191
negative symptoms, homovanillic acid, 41:191
negative symptoms, neuroleptics, 41:191
negative symptoms, prolactin, 41:191
negative symptoms, schizophrenia, 41:191
neuroleptics, dyskinesia, 41:191
neuroleptics, homovanillic acid, 41:191
neuroleptics, negative symptoms, 41:191
neuroleptics, prolactin, 41:191
neuroleptics, schizophrenia, 41:191
prolactin, dyskinesia, 41:191
prolactin, haloperidol, 41:191
prolactin, homovanillic acid, 41:191
prolactin, negative symptoms, 41:191
prolactin, neuroleptics, 41:191
prolactin, schizophrenia, 41:191
prolactin, side effects, 41:191
schizophrenia, dyskinesia, 41:191
schizophrenia, haloperidol, 41:191
schizophrenia, homovanillic acid, 41:191
schizophrenia, negative symptoms, 41:191
schizophrenia, neuroleptics, 41:191
schizophrenia, prolactin, 41:191
ACTH (adrenocorticotrophic hormone)
adolescents, beta-endorphin, 41:179
adolescents, exercise, 41:179
antidepressants, cortisol, 41:45
antidepressants, glucose, 41:45
antidepressants, insulin tolerance test, 41:45
antidepressants, normal subjects, 41:45
beta-endorphin, adolescents, 41:179

ACTH continued

beta-endorphin, exercise, 41:179
cortisol, antidepressants, 41:45
cortisol, glucose, 41:45
cortisol, imipramine, 41:45
cortisol, insulin tolerance test, 41:45
cortisol, normal subjects, 41:45
exercise, adolescents, 41:179
exercise, beta-endorphin, 41:179
glucose, antidepressants, 41:45
glucose, cortisol, 41:45
glucose, imipramine, 41:45
glucose, insulin tolerance test, 41:45
glucose, normal subjects, 41:45
imipramine, cortisol, 41:45
imipramine, glucose, 41:45
imipramine, insulin tolerance test, 41:45
imipramine, normal subjects, 41:45
insulin tolerance test, antidepressants, 41:45
insulin tolerance test, cortisol, 41:45
insulin tolerance test, glucose, 41:45
insulin tolerance test, imipramine, 41:45
insulin tolerance test, normal subjects, 41:45
MCPP, prolactin, 43:1
MCPP, schizophrenia, 43:1
MCPP, serotonin, 43:1
MCPP, temperature of body, 43:1
normal subjects, antidepressants, 41:45
normal subjects, cortisol, 41:45
normal subjects, glucose, 41:45
normal subjects, imipramine, 41:45
normal subjects, insulin tolerance test, 41:45
prolactin, MCPP, 43:1
prolactin, schizophrenia, 43:1
prolactin, serotonin, 43:1
prolactin, temperature of body, 43:1
schizophrenia, MCPP, 43:1
schizophrenia, prolactin, 43:1
schizophrenia, serotonin, 43:1
schizophrenia, temperature of body, 43:1
serotonin, MCPP, 43:1
serotonin, prolactin, 43:1
serotonin, schizophrenia, 43:1
serotonin, temperature of body, 43:1
temperature of body, MCPP, 43:1
temperature of body, prolactin, 43:1
temperature of body, schizophrenia, 43:1
temperature of body, serotonin, 43:1
Adolescents
ACTH, beta-endorphin, 41:179
ACTH, exercise, 41:179

Adolescents continued

- affective disorder, sleep, 41:53
- beta-endorphin, ACTH, 41:179
- beta-endorphin, exercise, 41:179
- exercise, ACTH, 41:179
- exercise, beta-endorphin, 41:179
- sleep, affective disorder, 41:53
- Adrenergic receptor**
 - affective disorder, blood pressure, 41:257
 - affective disorder, clonidine, 41:257
 - affective disorder, depressive symptoms, 41:257
 - affective disorder, electroconvulsive therapy, 41:257
 - affective disorder, growth hormone, 41:257
 - affective disorder, magnesium, 43:243
 - affective disorder, MHPG, 43:243
 - blood pressure, affective disorder, 41:257
 - blood pressure, clonidine, 41:257
 - blood pressure, depressive symptoms, 41:257
 - blood pressure, electroconvulsive therapy, 41:257
 - blood pressure, growth hormone, 41:257
 - clonidine, affective disorder, 41:257
 - clonidine, blood pressure, 41:257
 - clonidine, depressive symptoms, 41:257
 - clonidine, electroconvulsive therapy, 41:257
 - clonidine, growth hormone, 41:257
 - depressive symptoms, affective disorder, 41:257
 - depressive symptoms, blood pressure, 41:257
 - depressive symptoms, clonidine, 41:257
 - depressive symptoms, electroconvulsive therapy, 41:257
 - depressive symptoms, growth hormone, 41:257
 - electroconvulsive therapy, affective disorder, 41:257
 - electroconvulsive therapy, blood pressure, 41:257
 - electroconvulsive therapy, clonidine, 41:257
 - electroconvulsive therapy, depressive symptoms, 41:257
 - electroconvulsive therapy, growth hormone, 41:257
 - growth hormone, affective disorder, 41:257
 - growth hormone, blood pressure, 41:257
 - growth hormone, clonidine, 41:257
 - growth hormone, depressive symptoms, 41:257
 - growth hormone, electroconvulsive therapy, 41:257
 - magnesium, affective disorder, 43:243
 - magnesium, MHPG, 43:243
 - MHPG, affective disorder, 43:243

Adrenergic receptor continued

- MHPG, magnesium, 43:243
- Affective disorder**
 - adenosyl-L-methionine, antidepressants, 44:257
 - adenosyl-L-methionine, imipramine, 44:257
 - adinazolam, antidepressants, 43:177
 - adinazolam, desipramine, 43:177
 - adinazolam, melatonin, 43:177
 - adolescent depression, childhood depression, 41:53
 - adolescent depression, family studies, 41:53
 - adolescent depression, polysomnography, 41:53
 - adolescent depression, sleep, 41:53
 - adrenergic receptor, blood pressure, 41:257
 - adrenergic receptor, clonidine, 41:257
 - adrenergic receptor, depressive symptoms, 41:257
 - adrenergic receptor, electroconvulsive therapy, 41:257
 - adrenergic receptor, growth hormone, 41:257
 - adrenergic receptor, magnesium, 43:243
 - adrenergic receptor, MHPG, 43:243
 - age, cortisol, 44:9
 - age, dexamethasone suppression test, 44:9
 - age, sex differences, 44:9
 - agoraphobia, comorbidity, 42:171
 - agoraphobia, generalized anxiety disorder, 42:171
 - agoraphobia, panic disorder, 42:171
 - agoraphobia, panic disorder, 44:41
 - agoraphobia, polysomnography, 44:41
 - agoraphobia, sleep, 44:41
 - amino acids in plasma, obsessive-compulsive disorder, 44:91
 - aminoacids in plasma, tryptophan, 44:91
 - antidepressants, adenosyl-L-methionine, 44:257
 - antidepressants, adinazolam, 43:177
 - antidepressants, clinical features, 41:203
 - antidepressants, melatonin, 43:177
 - antidepressants, placebo, 41:203
 - antidepressants, response, 41:203
 - anxiety, comorbidity, 42:93
 - anxiety, dysthymia, 42:93
 - anxiety, MHPG, 42:295
 - anxiety, personality disorder, 42:93
 - augmenting-reducing, evoked potentials, 44:181
 - augmenting-reducing, lithium, 44:181
 - beta-endorphin, immunology, 43:111
 - beta-endorphin, natural killer cells, 43:111
 - bipolar, prodrome, 41:1
 - bipolar, relapse, 41:1
 - blood pressure, adrenergic receptor, 41:257

Affective disorder continued

blood pressure, clonidine, 41:257, 43:199
 blood pressure, depressive symptoms, 41:257
 blood pressure, electroconvulsive therapy, 41:257
 blood pressure, growth hormone, 41:257
 blood pressure, heart rate, 43:199
 blood pressure, MHPG, 43:199
 blood pressure, norepinephrine, 43:199
 childhood depression, adolescent depression, 41:53
 childhood depression, family studies, 41:53
 childhood depression, polysomnography, 41:53
 childhood depression, sleep, 41:53
 chronic medical illness burden, elderly, 41:237
 circadian rhythm, depressed mood, 43:147
 circadian rhythm, phototherapy, 43:147
 circadian rhythm, seasonal depression, 43:147
 circadian rhythms, social activity, 42:221
 clinical features, antidepressants, 41:203
 clinical features, placebo, 41:203
 clinical features, response, 41:203
 clonidine, adrenergic receptor, 41:257
 clonidine, blood pressure, 41:257, 43:199
 clonidine, depressive symptoms, 41:257
 clonidine, electroconvulsive therapy, 41:257
 clonidine, growth hormone, 41:257
 clonidine, heart rate, 43:199
 clonidine, MHPG, 43:199
 clonidine, norepinephrine, 43:199
 comorbidity, agoraphobia, 42:171
 comorbidity, anxiety, 42:93
 comorbidity, dysthymia, 42:93
 comorbidity, generalized anxiety disorder, 42:171
 comorbidity, genetics, 42:111
 comorbidity, obsessive-compulsive disorder, 42:111
 comorbidity, panic disorder, 42:171
 comorbidity, personality disorder, 42:93
 comorbidity, social phobia, 44:33
 comorbidity, treatment response, 44:33
 cortisol, age, 44:9
 cortisol, desipramine, 43:65, 44:237
 cortisol, dexamethasone suppression test, 44:9, 44:63, 44:227
 cortisol, dopamine, 43:31
 cortisol, epinephrine in urine, 43:31
 cortisol, fenfluramine, 43:137
 cortisol, magnetic resonance imaging, 44:63
 cortisol, MCPP, 43:65
 cortisol, melancholia, 43:137
 cortisol, monoamine oxidase, 44:1
 cortisol, norepinephrine, 43:65

Affective disorder continued

cortisol, norepinephrine in urine, 43:31
 cortisol, object loss, 44:227
 cortisol, panic disorder, 43:65
 cortisol, pituitary volume, 44:63
 cortisol, prolactin, 43:137
 cortisol, schizophrenia, 44:1
 cortisol, serotonin, 43:65, 43:137
 cortisol, sex differences, 44:9
 cortisol, suicide, 43:31
 delta EEG, polysomnography, 41:65
 delta EEG, sleep, 41:65
 depressed mood, circadian rhythm, 43:147
 depressed mood, emotion, 42:241
 depressed mood, facial affective discrimination, 42:241
 depressed mood, phototherapy, 43:147
 depressed mood, seasonal depression, 43:147
 depressive symptoms, adrenergic receptor, 41:257
 depressive symptoms, blood pressure, 41:257
 depressive symptoms, clonidine, 41:257
 depressive symptoms, electroconvulsive therapy, 41:257
 depressive symptoms, growth hormone, 41:257
 desipramine, adinazolam, 43:177
 desipramine, cortisol, 43:65, 44:237
 desipramine, MCPP, 43:65
 desipramine, melatonin, 43:177
 desipramine, norepinephrine, 43:65
 desipramine, panic disorder, 43:65
 desipramine, serotonin, 43:65
 dexamethasone suppression test, age, 44:9
 dexamethasone suppression test, cortisol, 44:9, 44:63, 44:237
 dexamethasone suppression test, magnetic resonance imaging, 44:63
 dexamethasone suppression test, object loss, 44:227
 dexamethasone suppression test, pituitary volume, 44:63
 dexamethasone suppression test, sex differences, 44:9
 dopamine, cortisol, 43:31
 dopamine, epinephrine in urine, 43:31
 dopamine, norepinephrine in urine, 43:31
 dopamine, suicide, 43:31
 dysthymia, anxiety, 42:93
 dysthymia, comorbidity, 42:93
 dysthymia, personality disorder, 42:93
 elderly, chronic medical illness burden, 41:237
 electroconvulsive therapy, adrenergic receptor, 41:257

Affective disorder continued

electroconvulsive therapy, blood pressure, 41:257
 electroconvulsive therapy, clonidine, 41:257
 electroconvulsive therapy, depressive symptoms, 41:257
 electroconvulsive therapy, growth hormone, 41:257
 electroretinography, seasonal depression, 43:55
 emotion, depressed mood, 42:241
 emotion, facial affective discrimination, 42:241
 epinephrine in urine, cortisol, 43:31
 epinephrine in urine, dopamine, 43:31
 epinephrine in urine, norepinephrine in urine, 43:31
 epinephrine in urine, suicide, 43:31
 evoked potentials, augmenting-reducing, 44:181
 evoked potentials, lithium, 44:181
 eye movements, paranoid subtype, 43:93
 eye movements, saccades, 43:93
 eye movements, schizophrenia, 43:93
 facial affective discrimination, depressed mood, 42:241
 facial affective discrimination, emotion, 42:241
 family studies, adolescent depression, 41:53
 family studies, childhood depression, 41:53
 family studies, polysomnography, 41:53
 family studies, sleep, 41:53
 fenfluramine, cortisol, 43:137
 fenfluramine, melancholia, 43:137
 fenfluramine, prolactin, 43:137
 fenfluramine, serotonin, 43:137
 generalized anxiety disorder, agoraphobia, 42:171
 generalized anxiety disorder, comorbidity, 42:171
 generalized anxiety disorder, panic disorder, 42:171
 genetics, comorbidity, 42:111
 genetics, obsessive-compulsive disorder, 42:111
 growth hormone, adrenergic receptor, 41:257
 growth hormone, blood pressure, 41:257
 growth hormone, clonidine, 41:257
 growth hormone, depressive symptoms, 41:257
 growth hormone, electroconvulsive therapy, 41:257
 heart rate, blood pressure, 43:199
 heart rate, clonidine, 43:199
 heart rate, MHPG, 43:199
 heart rate, norepinephrine, 43:199
 imipramine, adenosyl-L-methionine, 44:257
 imipramine, antidepressants, 44:257
 immunology, beta-endorphin, 43:111

Affective disorder continued

immunology, natural killer cells, 43:111
 ionselective electrode, lithium, 44:71
 ionselective electrode, whole blood measurement, 44:71
 light spectral value, phototherapy, 43:167
 light spectral value, seasonal depression, 43:167
 lithium, augmenting-reducing, 44:181
 lithium, evoked potentials, 44:181
 lithium, ion selective electrode, 44:71
 lithium, whole blood measurement, 44:71
 longitudinal studies, polysomnography, 42:27
 longitudinal studies, psychotherapy, 42:27
 longitudinal studies, remission, 42:27
 longitudinal studies, sleep, 42:27
 magnesium, adrenergic receptor, 43:243
 magnesium, MHPG, 43:243
 magnetic resonance imaging, cortisol, 44:63
 magnetic resonance imaging, dexamethasone suppression test, 44:63
 magnetic resonance imaging, pituitary volume, 44:63
 manic psychosis, perphenazine, 41:147
 manic psychosis, psychotic depression, 41:147
 manic psychosis, symptom response, 41:147
 manic symptoms, psychotic symptoms, 41:215
 manic symptoms, Tridimensional Personality Questionnaire, 41:215
 MCPP, cortisol, 43:65
 MCPP, desipramine, 43:65
 MCPP, norepinephrine, 43:65
 MCPP, panic disorder, 43:65
 MCPP, serotonin, 43:65
 melancholia, cortisol, 43:137
 melancholia, fenfluramine, 43:137
 melancholia, prolactin, 43:137
 melancholia, serotonin, 43:137
 melancholia, thyrotropin, 42:73
 melancholia, thyroxine, 42:73
 melancholia, triiodothyronine, 42:73
 melatonin, adinazolam, 43:177
 melatonin, antidepressants, 43:177
 melatonin, desipramine, 43:177
 MHPG, adrenergic receptor, 43:243
 MHPG, anxiety, 42:295
 MHPG, blood pressure, 43:199
 MHPG, clonidine, 43:199
 MHPG, heart rate, 43:199
 MHPG, magnesium, 43:243
 MHPG, norepinephrine, 43:199
 monoamine oxidase, cortisol, 44:1
 monoamine oxidase, schizophrenia, 44:1
 natural killer cells, beta-endorphin, 43:111

Affective disorder continued

natural killer cells, immunology, 43:111
 norepinephrine, blood pressure, 43:199
 norepinephrine, clonidine, 43:199
 norepinephrine, cortisol, 43:65
 norepinephrine, desipramine, 43:65
 norepinephrine, heart rate, 43:199
 norepinephrine in urine, cortisol, 43:31
 norepinephrine in urine, dopamine, 43:31
 norepinephrine in urine, epinephrine in urine, 43:31
 norepinephrine in urine, suicide, 43:31
 norepinephrine, MCPP, 43:65
 norepinephrine, MHPG, 43:199
 norepinephrine, panic disorder, 43:65
 norepinephrine, serotonin, 43:65
 object loss, cortisol, 44:227
 object loss, dexamethasone suppression test, 44:227
 obsessive-compulsive disorder, amino acids in plasma, 44:91
 obsessive-compulsive disorder, comorbidity, 42:111
 obsessive-compulsive disorder, genetics, 42:111
 obsessive-compulsive disorder, tryptophan, 44:91
 panic disorder, agoraphobia, 42:171, 44:41
 panic disorder, comorbidity, 42:171
 panic disorder, cortisol, 43:65
 panic disorder, desipramine, 43:65
 panic disorder, generalized anxiety disorder, 42:171
 panic disorder, MCPP, 43:65
 panic disorder, norepinephrine, 43:65
 panic disorder, polysomnography, 44:41
 panic disorder, serotonin, 43:65
 panic disorder, sleep, 44:41
 paranoid subtype, eye movements, 43:93
 paranoid subtype, saccades, 43:93
 paranoid subtype, schizophrenia, 43:93
 perphenazine, manic psychosis, 41:147
 perphenazine, psychotic depression, 41:147
 perphenazine, symptom response, 41:147
 personality disorder, anxiety, 42:93
 personality disorder, comorbidity, 42:93
 personality disorder, dysthymia, 42:93
 phototherapy, circadian rhythm, 43:147
 phototherapy, depressed mood, 43:147
 phototherapy, light spectral value, 43:167
 phototherapy, seasonal depression, 43:147, 43:167
 pituitary volume, cortisol, 44:63
 pituitary volume, dexamethasone suppression test, 44:63

Affective disorder continued

pituitary volume, magnetic resonance imaging, 44:63
 placebo, antidepressants, 41:203
 placebo, clinical features, 41:203
 placebo, response, 41:203
 polysomnography, adolescent depression, 41:53
 polysomnography, agoraphobia, 44:41
 polysomnography, childhood depression, 41:53
 polysomnography, delta EEG, 41:65
 polysomnography, family studies, 41:53
 polysomnography, longitudinal studies, 42:27
 polysomnography, panic disorder, 44:41
 polysomnography, psychotherapy, 42:13, 42:27
 polysomnography, remission, 42:27
 polysomnography, sleep, 41:53, 41:65, 42:13, 42:27, 44:41
 polysomnography, treatment response, 42:13
 prodrome, bipolar, 41:1
 prodrome, relapse, 41:1
 prolactin, cortisol, 43:137
 prolactin, fenfluramine, 43:137
 prolactin, melancholia, 43:137
 prolactin, serotonin, 43:137
 psychotherapy, longitudinal studies, 42:27
 psychotherapy, polysomnography, 42:13, 42:27
 psychotherapy, remission, 42:27
 psychotherapy, sleep, 42:13, 42:27
 psychotherapy, treatment response, 42:13
 psychotic depression, manic psychosis, 41:147
 psychotic depression, perphenazine, 41:147
 psychotic depression, symptom response, 41:147
 psychotic symptoms, manic symptoms, 41:215
 psychotic symptoms, Tridimensional Personality Questionnaire, relapse, bipolar, 41:1
 relapse, prodrome, 41:1
 remission, longitudinal studies, 42:27
 remission, polysomnography, 42:27
 remission, psychotherapy, 42:27
 remission, sleep, 42:27
 response, antidepressants, 41:203
 response, clinical features, 41:203
 response, placebo, 41:203
 saccades, eye movements, 43:93
 saccades, paranoid subtype, 43:93
 saccades, schizophrenia, 43:93
 schizophrenia, cortisol, 44:1
 schizophrenia, eye movements, 43:93
 schizophrenia, monoamine oxidase, 44:1
 schizophrenia, paranoid subtype, 43:93
 schizophrenia, saccades, 43:93

Affective disorder continued

- seasonal depression, circadian rhythm, 43:147
- seasonal depression, depressed mood, 43:147
- seasonal depression, electroretinography, 43:55
- seasonal depression, light spectral value, 43:167
- seasonal depression, phototherapy, 43:147, 43:167
- serotonin, cortisol, 43:65, 43:137
- serotonin, desipramine, 43:65
- serotonin, fenfluramine, 43:137
- serotonin, MCPP, 43:65
- serotonin, melancholia, 43:137
- serotonin, norepinephrine, 43:65
- serotonin, panic disorder, 43:65
- serotonin, prolactin, 43:137
- sex differences, age, 44:9
- sex differences, cortisol, 44:9
- sex differences, dexamethasone suppression test, 44:9
- sleep, adolescent depression, 41:53
- sleep, agoraphobia, 44:41
- sleep, childhood depression, 41:53
- sleep, delta EEG, 41:65
- sleep, family studies, 41:53
- sleep, longitudinal studies, 42:27
- sleep, panic disorder, 44:41
- sleep, polysomnography, 41:53, 41:65, 42:13, 42:27, 44:41
- sleep, psychotherapy, 42:13, 42:27
- sleep, remission, 42:27
- sleep, treatment response, 42:13
- socialactivity, circadian rhythms, 42:221
- social phobia, comorbidity, 44:33
- social phobia, treatment response, 44:33
- suicide, cortisol, 43:31
- suicide, dopamine, 43:31
- suicide, epinephrine in urine, 43:31
- suicide, norepinephrine in urine, 43:31
- symptom response, manic psychosis, 41:147
- symptom response, perphenazine, 41:147
- symptom response, psychotic depression, 41:147
- thyrotropin, melancholia, 42:73
- thyrotropin, thyroxine, 42:73
- thyrotropin, triiodothyronine, 42:73
- thyroxine, melancholia, 42:73
- thyroxine, thyrotropin, 42:73
- thyroxine, triiodothyronine, 42:73
- treatment response, comorbidity, 44:33
- treatment response, polysomnography, 42:13
- treatment response, psychotherapy, 42:13
- treatment response, sleep, 42:13
- treatment response, social phobia, 44:33

Affective disorder continued

- Tridimensional Personality Questionnaire, manic symptoms, 41:215
- Tridimensional Personality Questionnaire, psychotic symptoms, 41:215
- triiodothyronine, melancholia, 42:73
- triiodothyronine, thyrotropin, 42:73
- triiodothyronine, thyroxine, 42:73
- tryptophan, amino acids in plasma, 44:91
- tryptophan, obsessive-compulsive disorder, 44:91
- whole blood measurement, ion selective electrode, 44:71
- whole blood measurement, lithium, 44:71
- Aging**
- chronic medical illness burden, depression, 41:237
- chronic medical illness burden, geropsychiatry, 41:237
- depression, chronic medical illness burden, 41:237
- depression, geropsychiatry, 41:237
- geropsychiatry, chronic medical illness burden, 41:237
- geropsychiatry, depression, 41:237
- Alzheimer's disease**
- Blessed dementia scale, memory, 44:167
- diagnosis, neuropsychological tests, 44:93
- dopamine uptake, platelets, 41:17
- longitudinal course, memory, 42:101
- longitudinal course, sex differences, 42:101
- memory, Blessed dementia scale, 44:167
- memory, longitudinal course, 42:101
- memory, sex differences, 42:101
- neuropsychological tests, diagnosis, 44:93
- platelets, dopamine uptake, 41:17
- sex differences, longitudinal course, 42:101
- sex differences, memory, 42:101
- Antidepressants**
- ACTH, cortisol, 41:45
- ACTH, glucose, 41:45
- ACTH, imipramine, 41:45
- ACTH, insulin tolerance test, 41:45
- ACTH, normal subjects, 41:45
- adenosyl-L-methionine, affective disorder, 44:257
- adenosyl-L-methionine, imipramine, 44:257
- adinazolam, affective disorder, 43:177
- adinazolam, desipramine, 43:177
- adinazolam, melatonin, 43:177
- affective disorder, adenosyl-L-methionine, 44:257
- affective disorder, adinazolam, 43:177
- affective disorder, clinical features, 41:203

Antidepressants continued

affective disorder, desipramine, 43:177, 44:257
 affective disorder, imipramine, 44:257
 affective disorder, melatonin, 43:177
 affective disorder, placebo, 41:203
 affective disorder, response, 41:203
 clinical features, affective disorder, 41:203
 clinical features, placebo, 41:203
 clinical features, response, 41:203
 cortisol, ACTH, 41:45
 cortisol, glucose, 41:45
 cortisol, imipramine, 41:45
 cortisol, insulin tolerance test, 41:45
 cortisol, normal subjects, 41:45
 desipramine, adinazolam, 43:177
 desipramine, affective disorder, 43:177, 44:237
 desipramine, melatonin, 43:177
 glucose, ACTH, 41:45
 glucose, cortisol, 41:45
 glucose, imipramine, 41:45
 glucose, insulin tolerance test, 41:45
 glucose, normal subjects, 41:45
 imipramine, ACTH, 41:45
 imipramine, adenosyl-L-methionine, 44:257
 imipramine, affective disorder, 44:257
 imipramine, cortisol, 41:45
 imipramine, glucose, 41:45
 imipramine, insulin tolerance test, 41:45
 imipramine, normal subjects, 41:45
 insulin tolerance test, ACTH, 41:45
 insulin tolerance test, cortisol, 41:45
 insulin tolerance test, glucose, 41:45
 insulin tolerance test, imipramine, 41:45
 insulin tolerance test, normal subjects, 41:45
 melatonin, adinazolam, 43:177
 melatonin, affective disorder, 43:177
 melatonin, desipramine, 43:177
 normal subjects, ACTH, 41:45
 normal subjects, cortisol, 41:45
 normal subjects, glucose, 41:45
 normal subjects, imipramine, 41:45
 normal subjects, insulin tolerance test, 41:45
 placebo, affective disorder, 41:203
 placebo, clinical features, 41:203
 placebo, response, 41:203
 response, affective disorder, 41:203
 response, clinical features, 41:203
 response, placebo, 41:203
Beta-endorphin
 ACTH, adolescents, 41:179
 ACTH, exercise, 41:179
 adolescents, ACTH, 41:179
 adolescents, exercise, 41:179
 affective disorder, immunology, 43:111

Beta-endorphin continued

affective disorder, natural killer cells, 43:111
 exercise, ACTH, 41:179
 exercise, adolescents, 41:179
 immunology, affective disorder, 43:111
 immunology, natural killer cells, 43:111
 natural killer cells, affective disorder, 43:111
 natural killer cells, immunology, 43:111
Blood pressure
 adrenergic receptor, affective disorder, 41:257
 adrenergic receptor, clonidine, 41:257
 adrenergic receptor, depressive symptoms, 41:257
 adrenergic receptor, electroconvulsive therapy, 41:257
 adrenergic receptor, growth hormone, 41:257
 affective disorder, adrenergic receptor, 41:257
 affective disorder, clonidine, 41:257, 43:199
 affective disorder, depressive symptoms, 41:257
 affective disorder, electroconvulsive therapy, 41:257
 affective disorder, growth hormone, 41:257
 affective disorder, heart rate, 43:199
 affective disorder, MHPG, 43:199
 affective disorder, norepinephrine, 43:199
 clonidine, adrenergic receptor, 41:257
 clonidine, affective disorder, 41:257, 43:199
 clonidine, depressive symptoms, 41:257
 clonidine, electroconvulsive therapy, 41:257
 clonidine, growth hormone, 41:257
 clonidine, heart rate, 43:199
 clonidine, MHPG, 43:199
 clonidine, norepinephrine, 43:199
 depressive symptoms, adrenergic receptor, 41:257
 depressive symptoms, affective disorder, 41:257
 depressive symptoms, clonidine, 41:257
 depressive symptoms, electroconvulsive therapy, 41:257
 depressive symptoms, growth hormone, 41:257
 electroconvulsive therapy, adrenergic receptor, 41:257
 electroconvulsive therapy, affective disorder, 41:257
 electroconvulsive therapy, clonidine, 41:257
 electroconvulsive therapy, depressive symptoms, 41:257
 electroconvulsive therapy, growth hormone, 41:257
 growth hormone, adrenergic receptor, 41:257
 growth hormone, affective disorder, 41:257
 growth hormone, clonidine, 41:257
 growth hormone, depressive symptoms, 41:257
 growth hormone, electroconvulsive therapy, 41:257

Blood pressure continued

heart rate, affective disorder, 43:199
 heart rate, clonidine, 43:199
 heart rate, MHPG, 43:199
 heart rate, norepinephrine, 43:199
 MHPG, affective disorder, 43:199
 MHPG, clonidine, 43:199
 MHPG, heart rate, 43:199
 MHPG, norepinephrine, 43:199
 norepinephrine, affective disorder, 43:199
 norepinephrine, clonidine, 43:199
 norepinephrine, heart rate, 43:199
 norepinephrine, MHPG, 43:199

Circadian rhythms

affective disorder, depressed mood, 43:147
 affective disorder, phototherapy, 43:147
 affective disorder, seasonal depression, 43:147
 affective disorder, social activity, 42:221
 cortisol, melatonin, 43:161
 cortisol, platelet serotonin uptake, 43:161
 cortisol, prolactin, 43:161
 cortisol, serotonin, 43:161
 depressed mood, affective disorder, 43:147
 depressed mood, phototherapy, 43:147
 depressed mood, seasonal depression, 43:147
 growth hormone, schizophrenia, 41:155
 growth hormone, sleep, 41:155
 melatonin, cortisol, 43:161
 melatonin, platelet serotonin uptake, 43:161
 melatonin, prolactin, 43:161
 melatonin, serotonin, 43:161
 phototherapy, affective disorder, 43:147
 phototherapy, depressed mood, 43:147
 phototherapy, seasonal depression, 43:147
 platelet serotonin uptake, cortisol, 43:161
 platelet serotonin uptake, melatonin, 43:161
 platelet serotonin uptake, prolactin, 43:161
 platelet serotonin uptake, serotonin, 43:161
 prolactin, cortisol, 43:161
 prolactin, melatonin, 43:161
 prolactin, platelet serotonin uptake, 43:161
 prolactin, serotonin, 43:161
 schizophrenia, growth hormone, 41:155
 schizophrenia, sleep, 41:155
 seasonal depression, affective disorder, 43:147
 seasonal depression, depressed mood, 43:147
 seasonal depression, phototherapy, 43:147
 serotonin, cortisol, 43:161
 serotonin, melatonin, 43:161
 serotonin, platelet serotonin uptake, 43:161
 serotonin, prolactin, 43:161
 sleep, growth hormone, 41:155
 sleep, schizophrenia, 41:155
 social activity, affective disorder, 42:221

Clonidine

adrenergic receptor, affective disorder, 41:257
 adrenergic receptor, blood pressure, 41:257
 adrenergic receptor, depressive symptoms, 41:257
 adrenergic receptor, electroconvulsive therapy, 41:257
 adrenergic receptor, growth hormone, 41:257
 affective disorder, adrenergic receptor, 41:257
 affective disorder, blood pressure, 41:257, 43:199
 affective disorder, depressive symptoms, 41:257
 affective disorder, electroconvulsive therapy, 41:257
 affective disorder, growth hormone, 41:257
 affective disorder, heart rate, 43:199
 affective disorder, MHPG, 43:199
 affective disorder, norepinephrine, 43:199
 blood pressure, adrenergic receptor, 41:257
 blood pressure, affective disorder, 41:257, 43:199
 blood pressure, depressive symptoms, 41:257
 blood pressure, electroconvulsive therapy, 41:257
 blood pressure, growth hormone, 41:257
 blood pressure, heart rate, 43:199
 blood pressure, MHPG, 43:199
 blood pressure, norepinephrine, 43:199
 depressive symptoms, adrenergic receptor, 41:257
 depressive symptoms, affective disorder, 41:257
 depressive symptoms, blood pressure, 41:257
 depressive symptoms, electroconvulsive therapy, 41:257
 depressive symptoms, growth hormone, 41:257
 electroconvulsive therapy, adrenergic receptor, 41:257
 electroconvulsive therapy, affective disorder, 41:257
 electroconvulsive therapy, blood pressure, 41:257
 electroconvulsive therapy, depressive symptoms, 41:257
 electroconvulsive therapy, growth hormone, 41:257
 growth hormone, adrenergic receptor, 41:257
 growth hormone, affective disorder, 41:257
 growth hormone, blood pressure, 41:257
 growth hormone, depressive symptoms, 41:257
 growth hormone, electroconvulsive therapy, 41:257
 heart rate, affective disorder, 43:199

Clonidine continued

heart rate, blood pressure, 43:199
 heart rate, MHPG, 43:199
 heart rate, norepinephrine, 43:199
 MHPG, affective disorder, 43:199
 MHPG, blood pressure, 43:199
 MHPG, heart rate, 43:199
 MHPG, norepinephrine, 43:199
 norepinephrine, affective disorder, 43:199
 norepinephrine, blood pressure, 43:199
 norepinephrine, heart rate, 43:199
 norepinephrine, MHPG, 43:199

Clozapine

electroencephalography, epileptic seizures, 44:107
 electroencephalography, schizophrenia, 44:107
 epileptic seizures, electroencephalography, 44:107
 epileptic seizures, schizophrenia, 44:107
 eye movements, neuroleptics, 41:25
 eye movements, saccadic intrusions, 41:25
 eye movements, schizophrenia, 41:25
 neuroleptics, eye movements, 41:25
 neuroleptics, saccadic intrusions, 41:25
 neuroleptics, schizophrenia, 41:25
 saccadic intrusions, eye movements, 41:25
 saccadic intrusions, neuroleptics, 41:25
 saccadic intrusions, schizophrenia, 41:25
 schizophrenia, electroencephalography, 44:107
 schizophrenia, epileptic seizures, 44:107
 schizophrenia, eye movements, 41:25
 schizophrenia, neuroleptics, 41:25
 schizophrenia, saccadic intrusions, 41:25

Cortisol

ACTH, antidepressants, 41:45
 ACTH, glucose, 41:45
 ACTH, imipramine, 41:45
 ACTH, insulin tolerance test, 41:45
 ACTH, normal subjects, 41:45
 affective disorder, age, 44:9
 affective disorder, desipramine, 43:65, 44:237
 affective disorder, dexamethasone suppression test, 44:9, 44:63,
 affective disorder, dopamine, 43:31
 affective disorder, epinephrine in urine, 43:31
 affective disorder, fenfluramine, 43:137
 affective disorder, magnetic resonance imaging, 44:63
 affective disorder, MCPP, 43:65
 affective disorder, melancholia, 43:137
 affective disorder, monoamine oxidase, 44:1
 affective disorder, norepinephrine, 43:65
 affective disorder, norepinephrine in urine, 43:31

Cortisol

affective disorder, object loss, 44:227
 affective disorder, panic disorder, 43:65
 affective disorder, pituitary volume, 44:63
 affective disorder, prolactin, 43:137
 affective disorder, schizophrenia, 44:1
 affective disorder, serotonin, 43:65, 43:137
 affective disorder, sex differences, 44:9
 affective disorder, suicide, 43:31
 age, affective disorder, 44:9
 age, dexamethasone suppression test, 44:9
 age, sex differences, 44:9
 aggression, childhood disorders, 43:263
 aggression, disruptive behavior disorder, 43:263
 aggression, fenfluramine, 43:263
 aggression, prolactin, 43:263
 aggression, serotonin, 43:263
 antidepressants, ACTH, 41:45
 antidepressants, glucose, 41:45
 antidepressants, insulin tolerance test, 41:45
 antidepressants, normal subjects, 41:45
 attention deficit disorder, childhood disorders, 42:65
 attention deficit disorder, disruptive behavior disorders, 42:65
 attention deficit disorder, fenfluramine challenge, 42:65
 attention deficit disorder, prolactin, 42:65
 childhood disorders, aggression, 43:263
 childhood disorders, attention deficit disorder, 42:65
 childhood disorders, disruptive behavior disorder, 42:65, 43:263
 childhood disorders, fenfluramine, 43:263
 childhood disorders, fenfluramine challenge, 42:65
 childhood disorders, prolactin, 42:65, 43:263
 childhood disorders, serotonin, 43:263
 circadian rhythms, melatonin, 43:161
 circadian rhythms, platelet serotonin uptake, 43:161
 circadian rhythms, prolactin, 43:161
 circadian rhythms, serotonin, 43:161
 desipramine, affective disorder, 43:65, 44:237
 desipramine, MCPP, 43:65
 desipramine, norepinephrine, 43:65
 desipramine, panic disorder, 43:65
 desipramine, serotonin, 43:65
 dexamethasone suppression test, affective disorder, 44:9, 44:63, 44:227
 dexamethasone suppression test, age, 44:9
 dexamethasone suppression test, magnetic resonance imaging, 44:63

Cortisol continued

dexamethasone suppression test, object loss, 44:227

dexamethasone suppression test, pituitary volume, 44:63

dexamethasone suppression test, sex differences, 44:9

disruptive behavior disorder, aggression, 43:263

disruptive behavior disorder, attention deficit disorder, 42:65

disruptive behavior disorder, childhood disorders, 42:65, 43:263

disruptive behavior disorder, fenfluramine, 43:263

disruptive behavior disorder, fenfluramine challenge, 42:65

disruptive behavior disorder, prolactin, 42:65, 43:263

disruptive behavior disorder, serotonin, 43:263

dopamine, affective disorder, 43:31

dopamine, epinephrine in urine, 43:31

dopamine, norepinephrine in urine, 43:31

dopamine, suicide, 43:31

epinephrine in urine, affective disorder, 43:31

epinephrine in urine, dopamine, 43:31

epinephrine in urine, norepinephrine in urine, 43:31

epinephrine in urine, suicide, 43:31

fenfluramine, affective disorder, 43:137

fenfluramine, aggression, 43:263

fenfluramine challenge, attention deficit disorder, 42:65

fenfluramine challenge, childhood disorders, 42:65

fenfluramine challenge, disruptive behavior disorder, 42:65

fenfluramine challenge, prolactin, 42:65

fenfluramine, childhood disorders, 43:263

fenfluramine, disruptive behavior disorder, 43:263

fenfluramine, melancholia, 43:137

fenfluramine, prolactin, 43:137, 43:263

fenfluramine, serotonin, 43:137, 43:263

glucose, ACTH, 41:45

glucose, antidepressants, 41:45

glucose, imipramine, 41:45

glucose, insulin tolerance test, 41:45

glucose, normal subjects, 41:45

imipramine, ACTH, 41:45

imipramine, antidepressants, 41:45

imipramine, glucose, 41:45

imipramine, insulin tolerance test, 41:45

imipramine, normal subjects, 41:45

Cortisol continued

insulin tolerance test, ACTH, 41:45

insulin tolerance test, antidepressants, 41:45

insulin tolerance test, glucose, 41:45

insulin tolerance test, imipramine, 41:45

insulin tolerance test, normal subjects, 41:45

magnetic resonance imaging, affective disorder, 44:63

magnetic resonance imaging, dexamethasone suppression test, 44:63

magnetic resonance imaging, pituitary volume, 44:63

MCPP, affective disorder, 43:65

MCPP, desipramine, 43:65

MCPP, norepinephrine, 43:65

MCPP, panic disorder, 43:65

MCPP, serotonin, 43:65

melancholia, affective disorder, 43:137

melancholia, fenfluramine, 43:137

melancholia, prolactin, 43:137

melancholia, serotonin, 43:137

melatonin, circadian rhythms, 43:161

melatonin, obsessive-compulsive disorder, 44:217

melatonin, platelet serotonin uptake, 43:161

melatonin, prolactin, 43:161

melatonin, serotonin, 43:161

monoamine oxidase, affective disorder, 44:1

monoamine oxidase, schizophrenia, 44:1

norepinephrine, affective disorder, 43:65

norepinephrine, desipramine, 43:65

norepinephrine in urine, affective disorder, 43:31

norepinephrine in urine, dopamine, 43:31

norepinephrine in urine, epinephrine in urine, 43:31

norepinephrine in urine, suicide, 43:31

norepinephrine, MCPP, 43:65

norepinephrine, panic disorder, 43:65

norepinephrine, serotonin, 43:65

normal subjects, ACTH, 41:45

normal subjects, antidepressants, 41:45

normal subjects, glucose, 41:45

normal subjects, imipramine, 41:45

normal subjects, insulin tolerance test, 41:45

object loss, affective disorder, 44:227

object loss, dexamethasone suppression test, 44:227

obsessive-compulsive disorder, melatonin, 44:217

panic disorder, affective disorder, 43:65

panic disorder, desipramine, 43:65

panic disorder, MCPP, 43:65

panic disorder, norepinephrine, 43:65

Cortisol continued

- panic disorder, serotonin, 43:65
- pituitary volume, affective disorder, 44:63
- pituitary volume, dexamethasone suppression test, 44:63
- pituitary volume, magnetic resonance imaging, 44:63
- platelet serotonin uptake, circadian rhythms, 43:161
- platelet serotonin uptake, melatonin, 43:161
- platelet serotonin uptake, prolactin, 43:161
- platelet serotonin uptake, serotonin, 43:161
- prolactin, affective disorder, 43:137
- prolactin, aggression, 43:263
- prolactin, attention deficit disorder, 42:65
- prolactin, childhood disorders, 42:65, 43:263
- prolactin, circadian rhythms, 43:161
- prolactin, disruptive behavior disorder, 42:65, 43:263
- prolactin, fenfluramine, 43:137, 43:263
- prolactin, fenfluramine challenge, 42:65
- prolactin, melancholia, 43:137
- prolactin, melatonin, 43:161
- prolactin, platelet serotonin uptake, 43:161
- prolactin, serotonin, 43:137, 43:161, 43:263
- schizophrenia, affective disorder, 44:1
- schizophrenia, monoamine oxidase, 44:1
- serotonin, affective disorder, 43:65, 43:137
- serotonin, aggression, 43:263
- serotonin, childhood disorders, 43:263
- serotonin, circadian rhythms, 43:161
- serotonin, desipramine, 43:65
- serotonin, disruptive behavior disorder, 43:263
- serotonin, fenfluramine, 43:137, 43:263
- serotonin, MCPP, 43:65
- serotonin, melancholia, 43:137
- serotonin, melatonin, 43:161
- serotonin, norepinephrine, 43:65
- serotonin, panic disorder, 43:65
- serotonin, platelet serotonin uptake, 43:161
- serotonin, prolactin, 43:137, 43:161, 43:263
- sex differences, affective disorder, 44:9
- sex differences, age, 44:9
- sex differences, dexamethasone suppression test, 44:9
- suicide, affective disorders, 43:31
- suicide, dopamine, 43:31
- suicide, epinephrine in urine, 43:31
- suicide, norepinephrine in urine, 43:31
- Dementia**
- agitation, scale for assessment, 41:73
- scale for assessment, agitation, 41:73

Diazepam

- heart rate, norepinephrine, 41:89
- heart rate, normal men, 41:89
- heart rate, vagal tone, 41:89
- norepinephrine, heart rate, 41:89
- norepinephrine, normal men, 41:89
- norepinephrine, vagal tone, 41:89
- normal men, heart rate, 41:89
- normal men, norepinephrine, 41:89
- normal men, vagal tone, 41:89
- vagal tone, heart rate, 41:89
- vagal tone, norepinephrine, 41:89
- vagal tone, normal men, 41:89
- Dopamine**
- affective disorder, cortisol, 43:31
- affective disorder, epinephrine in urine, 43:31
- affective disorder, norepinephrine in urine, 43:31
- affective disorder, suicide, 43:31
- Alzheimer's disease, platelets, 41:17
- cortisol, affective disorder, 43:31
- cortisol, epinephrine in urine, 43:31
- cortisol, norepinephrine in urine, 43:31
- cortisol, suicide, 43:31
- delusional state, platelets, 41:17
- delusional state, schizophrenia, 41:17
- domperidone, growth hormone, 42:159
- domperidone, prolactin, 42:159
- domperidone, schizophrenia, 42:159
- epinephrine in urine, affective disorder, 43:31
- epinephrine in urine, cortisol, 43:31
- epinephrine in urine, norepinephrine in urine, 43:31
- epinephrine in urine, suicide, 43:31
- growth hormone, domperidone, 42:159
- growth hormone, prolactin, 42:159
- growth hormone, schizophrenia, 42:159
- norepinephrine in urine, affective disorder, 43:31
- norepinephrine in urine, cortisol, 43:31
- norepinephrine in urine, epinephrine in urine, 43:31
- norepinephrine in urine, suicide, 43:31
- platelets, Alzheimer's disease, 41:17
- platelets, delusional state, 41:17
- platelets, schizophrenia, 41:17
- prolactin, domperidone, 42:159
- prolactin, growth hormone, 42:159
- prolactin, schizophrenia, 42:159
- schizophrenia, delusional state, 41:17
- schizophrenia, domperidone, 42:159
- schizophrenia, growth hormone, 42:159
- schizophrenia, platelets, 41:17
- schizophrenia, prolactin, 42:159

Dopamine continued

- suicide, affective disorder, 43:31
- suicide, cortisol, 43:31
- suicide, epinephrine in urine, 43:31
- suicide, norepinephrine in urine, 43:31

Dyskinesia

- abnormal-movement disorders, haloperidol, 41:191
- abnormal-movement disorders, homovanillic acid, 41:191
- abnormal-movement disorders, negative symptoms, 41:191
- abnormal-movement disorders, neuroleptics, 41:191
- abnormal-movement disorders, prolactin, 41:191
- abnormal-movement disorders, schizophrenia, 41:191
- haloperidol, abnormal-movement disorders, 41:191
- haloperidol, homovanillic acid, 41:191
- haloperidol, negative symptoms, 41:191
- haloperidol, neuroleptics, 41:191
- haloperidol, prolactin, 41:191
- haloperidol, schizophrenia, 41:191
- homovanillic acid, abnormal-movement disorders, 41:191
- homovanillic acid, haloperidol, 41:191
- homovanillic acid, negative symptoms, 41:191
- homovanillic acid, neuroleptics, 41:191
- homovanillic acid, prolactin, 41:191
- homovanillic acid, schizophrenia, 41:191
- homovanillic acid, side effects, 41:191
- negative symptoms, abnormal-movement disorders, 41:191
- negative symptoms, haloperidol, 41:191
- negative symptoms, homovanillic acid, 41:191
- negative symptoms, neuroleptics, 41:191
- negative symptoms, prolactin, 41:191
- negative symptoms, schizophrenia, 41:191
- neuroleptics, abnormal-movement disorders, 41:191
- neuroleptics, haloperidol, 41:191
- neuroleptics, homovanillic acid, 41:191
- neuroleptics, negative symptoms, 41:191
- neuroleptics, prolactin, 41:191
- neuroleptics, schizophrenia, 41:191
- prolactin, abnormal-movement disorders, 41:191
- prolactin, haloperidol, 41:191
- prolactin, homovanillic acid, 41:191
- prolactin, negative symptoms, 41:191
- prolactin, neuroleptics, 41:191
- prolactin, schizophrenia, 41:191

Dyskinesia continued

- schizophrenia, abnormal-movement disorders, 41:191
- schizophrenia, haloperidol, 41:191
- schizophrenia, homovanillic acid, 41:191
- schizophrenia, negative symptoms, 41:191
- schizophrenia, neuroleptics, 41:191
- schizophrenia, prolactin, 41:191
- Electroconvulsive therapy**
- adrenergic receptor, affective disorder, 41:257
- adrenergic receptor, blood pressure, 41:257
- adrenergic receptor, clonidine, 41:257
- adrenergic receptor, depressive symptoms, 41:257
- adrenergic receptor, growth hormone, 41:257
- affective disorder, adrenergic receptor, 41:257
- affective disorder, blood pressure, 41:257
- affective disorder, clonidine, 41:257
- affective disorder, growth hormone, 41:257
- blood pressure, adrenergic receptor, 41:257
- blood pressure, affective disorder, 41:257
- blood pressure, clonidine, 41:257
- blood pressure, depressive symptoms, 41:257
- blood pressure, growth hormone, 41:257
- clonidine, adrenergic receptor, 41:257
- clonidine, affective disorder, 41:257
- clonidine, blood pressure, 41:257
- clonidine, depressive symptoms, 41:257
- clonidine, growth hormone, 41:257
- depressive symptoms, adrenergic receptor, 41:257
- depressive symptoms, blood pressure, 41:257
- depressive symptoms, clonidine, 41:257
- depressive symptoms, growth hormone, 41:257
- growth hormone, adrenergic receptor, 41:257
- growth hormone, affective disorder, 41:257
- growth hormone, blood pressure, 41:257
- growth hormone, clonidine, 41:257
- growth hormone, depressive symptoms, 41:257
- Evoked potentials**
- affective disorder, augmenting-reducing, 44:181
- affective disorder, lithium, 44:181
- augmenting-reducing, affective disorder, 44:181
- augmenting-reducing, lithium, 44:181
- eye movements, schizophrenia, 41:227
- lithium, affective disorder, 44:181
- lithium, augmenting-reducing, 44:181
- MHPG, norepinephrine, 44:21
- MHPG, schizophrenia, 44:21
- MHPG, sensory gating, 44:21
- norepinephrine, MHPG, 44:21

Evoked potentials continued

- norepinephrine, schizophrenia, 44:21
- norepinephrine, sensory gating, 44:21
- schizophrenia, eye movements, 41:227
- schizophrenia, MHPG, 44:21
- schizophrenia, norepinephrine, 44:21
- schizophrenia, sensory gating, 44:21
- sensory gating, MHPG, 44:21
- sensory gating, norepinephrine, 44:21
- sensory gating, schizophrenia, 44:21

Exercise

- ACTH, adolescents, 41:179
- ACTH, beta-endorphin, 41:179
- adolescents, ACTH, 41:179
- adolescents, beta-endorphin, 41:179
- beta-endorphin, ACTH, 41:179
- beta-endorphin, adolescents, 41:179

Expressed emotion

- content analysis, family interview, 41:275
- content analysis, relapse prediction, 41:275
- content analysis, schizophrenia, 41:275
- family interview, content analysis, 41:275
- family interview, relapse prediction, 41:275
- family interview, schizophrenia, 41:275
- relapse prediction, content analysis, 41:275
- relapse prediction, family interview, 41:275
- relapse prediction, schizophrenia, 41:275
- schizophrenia, content analysis, 41:275
- schizophrenia, family interview, 41:275
- schizophrenia, relapse prediction, 41:275

Eye movements

- affective disorder, paranoid subtype, 43:93
- affective disorder, saccades, 43:93
- affective disorder, schizophrenia, 43:93
- clozapine, neuroleptics, 41:25
- clozapine, saccadic intrusions, 41:25
- clozapine, schizophrenia, 41:25
- evoked potentials, schizophrenia, 41:227
- hand preference, intelligence, 41:115
- hand preference, laterality, 41:115
- hand preference, neuropsychological tests, 41:115
- hand preference, normal men, 41:115
- hand preference, schizotypy, 41:115
- intelligence, hand preference, 41:115
- intelligence, laterality, 41:115
- intelligence, neuropsychological tests, 41:115
- intelligence, normal men, 41:115
- intelligence, schizotypy, 41:115
- laterality, hand preference, 41:115
- laterality, intelligence, 41:115
- laterality, neuropsychological tests, 41:115
- laterality, normal men, 41:115
- laterality, schizotypy, 41:115

Eye movements continued

- neuroleptics, clozapine, 41:25
 - neuroleptics, saccadic intrusions, 41:25
 - neuroleptics, schizophrenia, 41:25
 - neuropsychological tests, hand preference, 41:115
 - neuropsychological tests, intelligence, 41:115
 - neuropsychological tests, laterality, 41:115
 - neuropsychological tests, normal men, 41:115
 - neuropsychological tests, schizotypy, 41:115
 - normal men, hand preference, 41:115
 - normal men, intelligence, 41:115
 - normal men, laterality, 41:115
 - normal men, neuropsychological tests, 41:115
 - normal men, schizotypy, 41:115
 - obsessive-compulsive disorder, smooth pursuit, 42:1
 - paranoid subtype, affective disorder, 43:93
 - paranoid subtype, saccades, 43:93
 - paranoid subtype, schizophrenia, 43:93
 - saccades, affective disorder, 43:93
 - saccades, paranoid subtype, 43:93
 - saccades, schizophrenia, 43:93
 - saccadic intrusions, clozapine, 41:25
 - saccadic intrusions, neuroleptics, 41:25
 - saccadic intrusions, schizophrenia, 41:25
 - schizophrenia, affective disorder, 43:93
 - schizophrenia, clozapine, 41:25
 - schizophrenia, evoked potentials, 41:227
 - schizophrenia, neuroleptics, 41:25
 - schizophrenia, paranoid subtype, 43:93
 - schizophrenia, saccades, 43:93
 - schizophrenia, saccadic intrusions, 41:25
 - schizotypy, hand preference, 41:115
 - schizotypy, intelligence, 41:115
 - schizotypy, laterality, 41:115
 - schizotypy, neuropsychological tests, 41:115
 - schizotypy, normal men, 41:115
 - smooth pursuit, obsessive-compulsive disorder, 42:1
- Family studies**
- adolescent depression, childhood depression, 41:53
 - adolescent depression, polysomnography, 41:53
 - adolescent depression, sleep, 41:53
 - affective disorder, adolescent depression, 41:53
 - affective disorder, childhood depression, 41:53
 - affective disorder, polysomnography, 41:53
 - affective disorder, sleep, 41:53
 - childhood depression, adolescent depression, 41:53

Family studies continued

childhood depression, polysomnography, 41:53
 childhood depression, sleep, 41:53
 polysomnography, adolescent depression, 41:53
 polysomnography, affective disorder, 41:53
 polysomnography, childhood depression, 41:53
 polysomnography, sleep, 41:53
 sleep, adolescent depression, 41:53
 sleep, affective disorder, 41:53
 sleep, childhood depression, 41:53
 sleep, polysomnography, 41:53

Frontal lobe

color naming, neuropsychological tests, 41:137
 color naming, schizophrenia, 41:137
 color naming, Stroop task, 41:137
 neuropsychological tests, color naming, 41:137
 neuropsychological tests, schizophrenia, 41:137
 schizophrenia, color naming, 41:137
 schizophrenia, neuropsychological tests, 41:137
 schizophrenia, Stroop task, 41:137
 Stroop task, color naming, 41:137
 Stroop task, schizophrenia, 41:137

Genetics

affective disorder, comorbidity, 42:111
 affective disorder, obsessive-compulsive disorder, 42:111
 age of onset, diagnostic subtypes, 41:107
 age of onset, schizophrenia, 41:107
 age of onset, siblings, 41:107
 assortative mating, schizotypal personality disorder, 41:283
 attention, high-risk study, 44:125
 attention, reaction time, 44:125
 attention, schizophrenia, 44:125
 chromosome 5, schizophrenia, 44:171
 comorbidity, affective disorder, 42:111
 comorbidity, obsessive-compulsive disorder, 42:111
 diagnostic subtypes, age of onset, 41:107
 diagnostic subtypes, schizophrenia, 41:107
 diagnostic subtypes, siblings, 41:107
 high-risk study, attention, 44:125
 high-risk study, reaction time, 44:125
 high-risk study, schizophrenia, 44:125
 HLA, linkage, 41:99
 HLA, multiplex families, 41:99
 HLA, schizophrenia, 41:99
 linkage, HLA, 41:99
 linkage, multiplex families, 41:99
 linkage, schizophrenia, 41:99
 multiplex families, HLA, 41:99
 multiplex families, linkage, 41:99

Genetics continued

multiplex families, schizophrenia, 41:99
 obsessive-compulsive disorder, affective disorder, 42:111
 obsessive-compulsive disorder, comorbidity, 42:111
 pupillometry, twin studies, 43:299
 reaction time, attention, 44:125
 reaction time, high-risk study, 44:125
 reaction time, schizophrenia, 44:125
 schizophrenia, age of onset, 41:107
 schizophrenia, attention, 44:125
 schizophrenia, chromosome 5, 44:171
 schizophrenia, diagnostic subtypes, 41:107
 schizophrenia, high-risk study, 44:125
 schizophrenia, HLA, 41:99
 schizophrenia, linkage, 41:99
 schizophrenia, multiplex families, 41:99
 schizophrenia, reaction time, 44:125
 schizophrenia, siblings, 41:107
 schizotypal personality disorder, assortative mating, 41:283
 siblings, age of onset, 41:107
 siblings, diagnostic subtypes, 41:107
 siblings, schizophrenia, 41:107
 twin studies, pupillometry, 43:299

Geropsychiatry
 aging, chronic medical illness burden, 41:237
 aging, depression, 41:237
 chronic medical illness burden, aging, 41:237
 chronic medical illness burden, depression, 41:237
 depression, aging, 41:237
 depression, chronic medical illness burden, 41:237

Glucose
 ACTH, antidepressants, 41:45
 ACTH, cortisol, 41:45
 ACTH, imipramine, 41:45
 ACTH, insulin tolerance test, 41:45
 ACTH, normal subjects, 41:45
 antidepressants, ACTH, 41:45
 antidepressants, cortisol, 41:45
 antidepressants, insulin tolerance test, 41:45
 antidepressants, normal subjects, 41:45
 cortisol, ACTH, 41:45
 cortisol, antidepressants, 41:45
 cortisol, imipramine, 41:45
 cortisol, insulin tolerance test, 41:45
 cortisol, normal subjects, 41:45
 imipramine, ACTH, 41:45
 imipramine, cortisol, 41:45
 imipramine, insulin tolerance test, 41:45
 imipramine, normal subjects, 41:45

Glucose continued

insulin tolerance test, ACTH, 41:45
 insulin tolerance test, antidepressants, 41:45
 insulin tolerance test, cortisol, 41:45
 insulin tolerance test, imipramine, 41:45
 insulin tolerance test, normal subjects, 41:45
 normal subjects, ACTH, 41:45
 normal subjects, antidepressants, 41:45
 normal subjects, cortisol, 41:45
 normal subjects, imipramine, 41:45
 normal subjects, insulin tolerance test, 41:45

Growth hormone

abstinence, carbidopa treatment, 43:77
 abstinence, cocaine, 43:77
 abstinence, homovanillic acid, 43:77
 abstinence, MHPG, 43:77
 abstinence, prolactin, 43:77
 abstinence, substance abuse, 43:77
 adrenergic receptor, affective disorder, 41:257
 adrenergic receptor, blood pressure, 41:257
 adrenergic receptor, clonidine, 41:257
 adrenergic receptor, depressive symptoms, 41:257
 adrenergic receptor, electroconvulsive therapy, 41:257
 affective disorder, adrenergic receptor, 41:257
 affective disorder, blood pressure, 41:257
 affective disorder, clonidine, 41:257
 affective disorder, electroconvulsive therapy, 41:257
 blood pressure, adrenergic receptor, 41:257
 blood pressure, affective disorder, 41:257
 blood pressure, clonidine, 41:257
 blood pressure, depressive symptoms, 41:257
 blood pressure, electroconvulsive therapy, 41:257
 carbidopa treatment, abstinence, 43:77
 carbidopa treatment, cocaine, 43:77
 carbidopa treatment, homovanillic acid, 43:77
 carbidopa treatment, MHPG, 43:77
 carbidopa treatment, prolactin, 43:77
 carbidopa treatment, substance abuse, 43:77
 circadian rhythm, schizophrenia, 41:155
 circadian rhythm, sleep, 41:155
 clonidine, adrenergic receptor, 41:257
 clonidine, affective disorder, 41:257
 clonidine, blood pressure, 41:257
 clonidine, depressive symptoms, 41:257
 clonidine, electroconvulsive therapy, 41:257
 cocaine, abstinence, 43:77
 cocaine, carbidopa treatment, 43:77
 cocaine, homovanillic acid, 43:77
 cocaine, MHPG, 43:77
 cocaine, prolactin, 43:77

Growth hormone continued

cocaine, substance abuse, 43:77
 depressive symptoms, adrenergic receptor, 41:257
 depressive symptoms, blood pressure, 41:257
 depressive symptoms, clonidine, 41:257
 depressive symptoms, electroconvulsive therapy, 41:257
 domperidone, dopamine, 42:159
 domperidone, prolactin, 42:159
 domperidone, schizophrenia, 42:159
 dopamine, domperidone, 42:159
 dopamine, prolactin, 42:159
 dopamine, schizophrenia, 42:159
 electroconvulsive therapy, adrenergic receptor, 41:257
 electroconvulsive therapy, affective disorder, 41:257
 electroconvulsive therapy, blood pressure, 41:257
 electroconvulsive therapy, clonidine, 41:257
 electroconvulsive therapy, depressive symptoms, 41:257
 homovanillic acid, abstinence, 43:77
 homovanillic acid, carbidopa treatment, 43:77
 homovanillic acid, cocaine, 43:77
 homovanillic acid, MHPG, 43:77
 homovanillic acid, prolactin, 43:77
 homovanillic acid, substance abuse, 43:77
 MHPG, abstinence, 43:77
 MHPG, carbidopa treatment, 43:77
 MHPG, cocaine, 43:77
 MHPG, homovanillic acid, 43:77
 MHPG, prolactin, 43:77
 MHPG, substance abuse, 43:77
 prolactin, abstinence, 43:77
 prolactin, carbidopa treatment, 43:77
 prolactin, cocaine, 43:77
 prolactin, domperidone, 42:159
 prolactin, dopamine, 42:159
 prolactin, homovanillic acid, 43:77
 prolactin, MHPG, 43:77
 prolactin, schizophrenia, 42:159
 prolactin, substance abuse, 43:77
 schizophrenia, circadian rhythm, 41:155
 schizophrenia, domperidone, 42:159
 schizophrenia, dopamine, 42:159
 schizophrenia, prolactin, 42:159
 schizophrenia, sleep, 41:155
 sleep, circadian rhythm, 41:155
 sleep, schizophrenia, 41:155
 substance abuse, abstinence, 43:77
 substance abuse, carbidopa treatment, 43:77
 substance abuse, cocaine, 43:77

Growth hormone continued

substance abuse, homovanillic acid, 43:77

substance abuse, MHPG, 43:77

substance abuse, prolactin, 43:77

Haloperidol

abnormal-movement disorders, dyskinesia, 41:191

abnormal-movement disorders, homovanillic acid, 41:191

abnormal-movement disorders, negative symptoms, 41:191

abnormal-movement disorders, neuroleptics, 41:191

abnormal-movement disorders, prolactin, 41:191

abnormal-movement disorders, schizophrenia, 41:191

dyskinesia, homovanillic acid, 41:191

dyskinesia, negative symptoms, 41:191

dyskinesia, prolactin, 41:191

dyskinesia, schizophrenia, 41:191

EEG, neuroleptics, 42:129

EEG, schizophrenia, 42:129

EEG, treatment response, 42:129

homovanillic acid, abnormal-movement disorders, 41:191

homovanillic acid, dyskinesia, 41:191

homovanillic acid, negative symptoms, 41:191

homovanillic acid, prolactin, 41:191

homovanillic acid, schizophrenia, 41:191

homovanillic acid, side effects, 41:191

negative symptoms, abnormal-movement disorders, 41:191

negative symptoms, dyskinesia, 41:191

negative symptoms, homovanillic acid, 41:191

negative symptoms, prolactin, 41:191

negative symptoms, schizophrenia, 41:191

negative symptoms, side effects, 41:191

prolactin, abnormal-movement disorders, 41:191

prolactin, dyskinesia, 41:191

prolactin, homovanillic acid, 41:191

prolactin, negative symptoms, 41:191

prolactin, schizophrenia, 41:191

prolactin, side effects, 41:191

pupillometry, relapse, 43:287

pupillometry, schizophrenia, 43:287

relapse, pupillometry, 43:287

relapse, schizophrenia, 43:287

schizophrenia, abnormal-movement disorders, 41:191

schizophrenia, dyskinesia, 41:191

schizophrenia, EEG, 42:129

schizophrenia, homovanillic acid, 41:191

Haloperidol continued

schizophrenia, negative symptoms, 41:191

schizophrenia, prolactin, 41:191

schizophrenia, pupillometry, 43:287

schizophrenia, relapse, 43:287

schizophrenia, side effects, 41:191

schizophrenia, treatment response, 42:129

side effects, homovanillic acid, 41:191

side effects, negative symptoms, 41:191

side effects, prolactin, 41:191

side effects, schizophrenia, 41:191

treatment response, EEG, 42:129

treatment response, schizophrenia, 42:129

5-HIAA (5-hydroxyindoleacetic acid)

indole-3-acetic acid, obsessive-compulsive disorder, 41:267

indole-3-acetic acid, serotonin, 41:267

indole-3-acetic acid, Tourette's syndrome, 41:267

indole-3-acetic acid, tryptamine, 41:267

obsessive-compulsive disorder, indole-3-acetic acid, 41:267

obsessive-compulsive disorder, serotonin, 41:267

obsessive-compulsive disorder, Tourette's syndrome, 41:267

obsessive-compulsive disorder, tryptamine, 41:267

serotonin, indole-3-acetic acid, 41:267

serotonin, obsessive-compulsive disorder, 41:267

serotonin, Tourette's syndrome, 41:267

serotonin, tryptamine, 41:267

Tourette's syndrome, indole-3-acetic acid, 41:267

Tourette's syndrome, obsessive-compulsive disorder, 41:267

Tourette's syndrome, serotonin, 41:267

Tourette's syndrome, tryptamine, 41:267

tryptamine, indole-3-acetic acid, 41:267

tryptamine, obsessive-compulsive disorder, 41:267

tryptamine, serotonin, 41:267

tryptamine, Tourette's syndrome, 41:267

Heart rate

affective disorder, blood pressure, 43:199

affective disorder, clonidine, 43:199

affective disorder, MHPG, 43:199

affective disorder, norepinephrine, 43:199

blood pressure, affective disorder, 43:199

blood pressure, clonidine, 43:199

blood pressure, MHPG, 43:199

blood pressure, norepinephrine, 43:199

clonidine, affective disorder, 43:199

Heart rate continued

- clonidine, blood pressure, 43:199
- clonidine, MHPG, 43:199
- clonidine, norepinephrine, 43:199
- diazepam, norepinephrine, 41:89
- diazepam, normal men, 41:89
- MHPG, affective disorder, 43:199
- MHPG, blood pressure, 43:199
- MHPG, clonidine, 43:199
- MHPG, norepinephrine, 43:199
- norepinephrine, affective disorder, 43:199
- norepinephrine, blood pressure, 43:199
- norepinephrine, clonidine, 43:199
- norepinephrine, diazepam, 41:89
- norepinephrine, MHPG, 43:199
- norepinephrine, normal men, 41:89
- norepinephrine, vagal tone, 41:89
- normal men, diazepam, 41:89
- normal men, norepinephrine, 41:89
- normal men, vagal tone, 41:89
- vagal tone, diazepam, 41:89
- vagal tone, norepinephrine, 41:89
- vagal tone, normal men, 41:89
- HIV** (human immunodeficiency virus)
- neuropsychological tests, substance abuse, 41:163
- substance abuse, neuropsychological tests, 41:163

HLA (human leukocyte antigen)

- genetics, linkage, 41:99
- genetics, multiplex families, 41:99
- genetics, schizophrenia, 41:99
- linkage, genetics, 41:99
- linkage, multiplex families, 41:99
- linkage, schizophrenia, 41:99
- multiplex families, genetics, 41:99
- multiplex families, linkage, 41:99
- multiplex families, schizophrenia, 41:99
- schizophrenia, genetics, 41:99
- schizophrenia, linkage, 41:99
- schizophrenia, multiplex families, 41:99

Homovanillic acid

- abnormal-movement disorders, haloperidol, 41:191
- abnormal-movement disorders, negative symptoms, 41:191
- abnormal-movement disorders, neuroleptics, 41:191
- abnormal-movement disorders, prolactin, 41:191
- abnormal-movement disorders, schizophrenia, 41:191
- abstinence, carbidopa treatment, 43:77
- abstinence, cocaine, 43:77

Homovanillic acid continued

- abstinence, growth hormone, 43:77
- abstinence, MHPG, 43:77
- abstinence, prolactin, 43:77
- abstinence, substance abuse, 43:77
- carbidopa treatment, abstinence, 43:77
- carbidopa treatment, cocaine, 43:77
- carbidopa treatment, growth hormone, 43:77
- carbidopa treatment, MHPG, 43:77
- carbidopa treatment, prolactin, 43:77
- carbidopa treatment, substance abuse, 43:77
- cocaine, abstinence, 43:77
- cocaine, carbidopa treatment, 43:77
- cocaine, growth hormone, 43:77
- cocaine, MHPG, 43:77
- cocaine, prolactin, 43:77
- cocaine, substance abuse, 43:77
- dyskinesia, haloperidol, 41:191
- dyskinesia, negative symptoms, 41:191
- dyskinesia, neuroleptics, 41:191
- dyskinesia, prolactin, 41:191
- dyskinesia, schizophrenia, 41:191
- fenfluramine, obsessive-compulsive disorder, 42:185
- growth hormone, abstinence, 43:77
- growth hormone, carbidopa treatment, 43:77
- growth hormone, cocaine, 43:77
- growth hormone, MHPG, 43:77
- growth hormone, prolactin, 43:77
- growth hormone, substance abuse, 43:77
- haloperidol, abnormal-movement disorders, 41:191
- haloperidol, dyskinesia, 41:191
- haloperidol, negative symptoms, 41:191
- haloperidol, neuroleptics, 41:191
- haloperidol, prolactin, 41:191
- haloperidol, schizophrenia, 41:191
- haloperidol, side effects, 41:191
- MHPG, abstinence, 43:77
- MHPG, carbidopa treatment, 43:77
- MHPG, cocaine, 43:77
- MHPG, growth hormone, 43:77
- MHPG, prolactin, 43:77
- MHPG, substance abuse, 43:77
- negative symptoms, abnormal-movement disorders, 41:191
- negative symptoms, dyskinesia, 41:191
- negative symptoms, haloperidol, 41:191
- negative symptoms, neuroleptics, 41:191
- negative symptoms, prolactin, 41:191
- negative symptoms, schizophrenia, 41:191
- negative symptoms, side effects, 41:191
- neuroleptics, abnormal-movement disorders, 41:191

Homovanillic acid continued

neuroleptics, dyskinesia, 41:191
 neuroleptics, negative symptoms, 41:191
 neuroleptics, prolactin, 41:191
 neuroleptics, schizophrenia, 41:191
 neuroleptics, side effects, 41:191
 neuropsychological tasks, Tourette's syndrome, 43:277
 neuropsychological tasks, trace amines, 43:277
 obsessive-compulsive disorder, fenfluramine, 42:185
 prolactin, abnormal-movement disorders, 41:191
 prolactin, abstinence, 43:77
 prolactin, carbidopa treatment, 43:77
 prolactin, cocaine, 43:77
 prolactin, dyskinesia, 41:191
 prolactin, growth hormone, 43:77
 prolactin, haloperidol, 41:191
 prolactin, MHPG, 43:77
 prolactin, negative symptoms, 41:191
 prolactin, neuroleptics, 41:191
 prolactin, schizophrenia, 41:191
 prolactin, side effects, 41:191
 prolactin, substance abuse, 43:77
 schizophrenia, abnormal-movement disorders, 41:191
 schizophrenia, dyskinesia, 41:191
 schizophrenia, haloperidol, 41:191
 schizophrenia, negative symptoms, 41:191
 schizophrenia, neuroleptics, 41:191
 schizophrenia, prolactin, 41:191
 schizophrenia, side effects, 41:191
 side effects, haloperidol, 41:191
 side effects, negative symptoms, 41:191
 side effects, neuroleptics, 41:191
 side effects, prolactin, 41:191
 side effects, schizophrenia, 41:191
 substance abuse, abstinence, 43:77
 substance abuse, carbidopa treatment, 43:77
 substance abuse, cocaine, 43:77
 substance abuse, growth hormone, 43:77
 substance abuse, MHPG, 43:77
 substance abuse, prolactin, 43:77
 Tourette's syndrome, neuropsychological tasks, 43:277
 Tourette's syndrome, trace amines, 43:277
 trace amines, neuropsychological tasks, 43:277
 trace amines, Tourette's syndrome, 43:277

Imipramine

ACTH, antidepressants, 41:45
 ACTH, cortisol, 41:45

Imipramine continued

ACTH, glucose, 41:45
 ACTH, insulin tolerance test, 41:45
 ACTH, normal subjects, 41:45
 adenosyl-L-methionine, affective disorder, 44:257
 adenosyl-L-methionine, antidepressants, 44:257
 affective disorder, adenosyl-L-methionine, 44:257
 affective disorder, antidepressants, 44:257
 antidepressants, ACTH, 41:45
 antidepressants, adenosyl-L-methionine, 44:257
 antidepressants, affective disorder, 44:257
 antidepressants, cortisol, 41:45
 antidepressants, glucose, 41:45
 antidepressants, insulin tolerance test, 41:45
 antidepressants, normal subjects, 41:45
 cortisol, ACTH, 41:45
 cortisol, antidepressants, 41:45
 cortisol, glucose, 41:45
 cortisol, insulin tolerance test, 41:45
 cortisol, normal subjects, 41:45
 glucose, ACTH, 41:45
 glucose, antidepressants, 41:45
 glucose, cortisol, 41:45
 glucose, insulin tolerance test, 41:45
 glucose, normal subjects, 41:45
 insulin tolerance test, ACTH, 41:45
 insulin tolerance test, antidepressants, 41:45
 insulin tolerance test, cortisol, 41:45
 insulin tolerance test, glucose, 41:45
 insulin tolerance test, normal subjects, 41:45
 normal subjects, ACTH, 41:45
 normal subjects, antidepressants, 41:45
 normal subjects, cortisol, 41:45
 normal subjects, glucose, 41:45
 normal subjects, insulin tolerance test, 41:45
 obsessive-compulsive disorder, platelet imipramine binding, 42:41
 obsessive-compulsive disorder, serotonin, 42:41
 obsessive-compulsive disorder, sulfotransferase in platelets, 42:41
 platelet imipramine binding, obsessive-compulsive disorder, 42:41
 platelet imipramine binding, serotonin, 42:41
 platelet imipramine binding, sulfotransferase in platelets, 42:41
 serotonin, obsessive-compulsive disorder, 42:41
 serotonin, platelet imipramine binding, 42:41
 serotonin, sulfotransferase in platelets, 42:41
 sulfotransferase in platelets, obsessive-compulsive disorder, 42:41

Imipramine continued

- sulfotransferase in platelets, platelet imipramine binding, 42:41
- sulfotransferase in platelets, serotonin, 42:41
- Indole-3-acetic acid**
- 5-HIAA, obsessive-compulsive disorder, 41:267
- 5-HIAA, serotonin, 41:267
- 5-HIAA, Tourette's syndrome, 41:267
- 5-HIAA, tryptamine, 41:267
- obsessive-compulsive disorder, 5-HIAA, 41:267
- obsessive-compulsive disorder, serotonin, 41:267
- obsessive-compulsive disorder, Tourette's syndrome, 41:267
- obsessive-compulsive disorder, tryptamine, 41:267
- serotonin, 5-HIAA, 41:267
- serotonin, obsessive-compulsive disorder, 41:267
- serotonin, Tourette's syndrome, 41:267
- serotonin, tryptamine, 41:267
- Tourette's syndrome, 5-HIAA, 41:267
- Tourette's syndrome, obsessive-compulsive disorder, 41:267
- Tourette's syndrome, serotonin, 41:267
- Tourette's syndrome, tryptamine, 41:267
- tryptamine, 5-HIAA, 41:267
- tryptamine, obsessive-compulsive disorder, 41:267
- tryptamine, serotonin, 41:267
- tryptamine, Tourette's syndrome, 41:267

Insulin tolerance test

- ACTH, antidepressants, 41:45
- ACTH, cortisol, 41:45
- ACTH, glucose, 41:45
- ACTH, imipramine, 41:45
- ACTH, normal subjects, 41:45
- antidepressants, ACTH, 41:45
- antidepressants, cortisol, 41:45
- antidepressants, glucose, 41:45
- antidepressants, normal subjects, 41:45
- cortisol, ACTH, 41:45
- cortisol, antidepressants, 41:45
- cortisol, glucose, 41:45
- cortisol, imipramine, 41:45
- cortisol, normal subjects, 41:45
- glucose, ACTH, 41:45
- glucose, antidepressants, 41:45
- glucose, cortisol, 41:45
- glucose, imipramine, 41:45
- glucose, normal subjects, 41:45
- imipramine, ACTH, 41:45
- imipramine, cortisol, 41:45

Insulin tolerance test continued

- imipramine, glucose, 41:45
- imipramine, normal subjects, 41:45
- normal subjects, ACTH, 41:45
- normal subjects, antidepressants, 41:45
- normal subjects, cortisol, 41:45
- normal subjects, glucose, 41:45
- normal subjects, imipramine, 41:45
- Intelligence**
- eye movements, hand preference, 41:115
- eye movements, laterality, 41:115
- eye movements, neuropsychological tests, 41:115
- eye movements, normal men, 41:115
- eye movements, schizotypy, 41:115
- hand preference, eye movements, 41:115
- hand preference, laterality, 41:115
- hand preference, neuropsychological tests, 41:115
- hand preference, normal men, 41:115
- hand preference, schizotypy, 41:115
- laterality, eye movements, 41:115
- laterality, hand preference, 41:115
- laterality, neuropsychological tests, 41:115
- laterality, normal men, 41:115
- laterality, schizotypy, 41:115
- neuropsychological tests, eye movements, 41:115
- neuropsychological tests, hand preference, 41:115
- neuropsychological tests, laterality, 41:115
- neuropsychological tests, normal men, 41:115
- neuropsychological tests, schizotypy, 41:115
- normal men, eye movements, 41:115
- normal men, hand preference, 41:115
- normal men, laterality, 41:115
- normal men, neuropsychological tests, 41:115
- normal men, schizotypy, 41:115
- schizotypy, eye movements, 41:115
- schizotypy, hand preference, 41:115
- schizotypy, laterality, 41:115
- schizotypy, neuropsychological tests, 41:115
- schizotypy, normal men, 41:115
- Laterality**
- attention, negative symptoms, 43:87
- attention, reaction time, 43:87
- attention, schizophrenia, 43:87
- emotion, facial affective discrimination, 42:231
- emotion, sex differences, 42:231
- eye movements, hand preference, 41:115
- eye movements, intelligence, 41:115
- eye movements, neuropsychological tests, 41:115
- eye movements, normal men, 41:115

Laterality continued

- eye movements, schizotypy, 41:115
- facial affective discrimination, emotion, 42:231
- facial affective discrimination, sex differences, 42:231
- hand preference, eye movements, 41:115
- hand preference, intelligence, 41:115
- hand preference, neuropsychological tests, 41:115
- hand preference, normal men, 41:115
- hand preference, schizotypy, 41:115
- intelligence, eye movements, 41:115
- intelligence, hand preference, 41:115
- intelligence, neuropsychological tests, 41:115
- intelligence, normal men, 41:115
- intelligence, schizotypy, 41:115
- negative symptoms, attention, 43:87
- negative symptoms, reaction time, 43:87
- negative symptoms, schizophrenia, 43:87
- neuropsychological tests, eye movements, 41:115
- neuropsychological tests, hand preference, 41:115
- neuropsychological tests, intelligence, 41:115
- neuropsychological tests, normal men, 41:115
- neuropsychological tests, schizotypy, 41:115
- normal men, eye movements, 41:115
- normal men, hand preference, 41:115
- normal men, intelligence, 41:115
- normal men, neuropsychological tests, 41:115
- normal men, schizotypy, 41:115
- reaction time, attention, 43:87
- reaction time, negative symptoms, 43:87
- reaction time, schizophrenia, 43:87
- schizophrenia, attention, 43:87
- schizophrenia, negative symptoms, 43:87
- schizophrenia, reaction time, 43:87
- schizotypy, eye movements, 41:115
- schizotypy, hand preference, 41:115
- schizotypy, intelligence, 41:115
- schizotypy, neuropsychological tests, 41:115
- schizotypy, normal men, 41:115
- sex differences, emotion, 42:231
- sex differences, facial affective discrimination, 42:231

Neuroleptics

- abnormal-movement disorders, homovanillic acid, 41:191
- abnormal-movement disorders, negative symptoms, 41:191
- abnormal-movement disorders, prolactin, 41:191
- abnormal-movement disorders, schizophrenia, 41:191

Neuroleptics continued

- bioassay vs. radioimmunoassay, prolactin, 41:249
- bioassay vs. radioimmunoassay, schizophrenia, 41:249
- ceruletide, schizophrenia, 43:129
- ceruletide, side effects, 43:129
- ceruletide, tardive dyskinesia, 43:129
- clozapine, eye movements, 41:25
- clozapine, saccadic intrusions, 41:25
- clozapine, schizophrenia, 41:25
- dyskinesia, haloperidol, 41:191
- dyskinesia, homovanillic acid, 41:191
- dyskinesia, negative symptoms, 41:191
- dyskinesia, prolactin, 41:191
- dyskinesia, schizophrenia, 41:191
- dyskinesia, side effects, 41:191
- EEG, haloperidol, 42:129
- EEG, schizophrenia, 42:129
- EEG, treatment response, 42:129
- electrodermal activity, positive symptoms, 42:145
- electrodermal activity, schizophrenia, 42:145
- eye movements, clozapine, 41:25
- eye movements, saccadic intrusions, 41:25
- eye movements, schizophrenia, 41:25
- haloperidol, abnormal-movement disorders, 41:191
- haloperidol, dyskinesia, 41:191
- haloperidol, EEG, 42:129
- haloperidol, homovanillic acid, 41:191
- haloperidol, negative symptoms, 41:191
- haloperidol, prolactin, 41:191
- haloperidol, pupillometry, 43:287
- haloperidol, relapse, 43:287
- haloperidol, schizophrenia, 41:191, 42:129, 43:287
- haloperidol, side effects, 41:191
- haloperidol, treatment response, 42:129
- homovanillic acid, abnormal-movement disorders, 41:191
- homovanillic acid, dyskinesia, 41:191
- homovanillic acid, haloperidol, 41:191
- homovanillic acid, negative symptoms, 41:191
- homovanillic acid, prolactin, 41:191
- homovanillic acid, schizophrenia, 41:191
- homovanillic acid, side effects, 41:191
- negative symptoms, abnormal-movement disorders, 41:191
- negative symptoms, dyskinesia, 41:191
- negative symptoms, haloperidol, 41:191
- negative symptoms, homovanillic acid, 41:191
- negative symptoms, prolactin, 41:191
- negative symptoms, schizophrenia, 41:191

Neuroleptics continued

negative symptoms, side effects, 41:191
 neuroleptic malignant syndrome,
 schizophrenia, 44:251
 neuroleptic malignant syndrome, temperature,
 44:251
 Parkinsonism, schizophrenia, 41:9
 Parkinsonism, side effects, 41:9
 Parkinsonism, terguride, 41:9
 perphenazine, psychosis, 41:147
 perphenazine, symptom response, 41:147
 positive symptoms, electrodermal activity, 42:145
 positive symptoms, schizophrenia, 42:145
 prolactin, abnormal-movement disorders,
 41:191
 prolactin, bioassay vs. radioimmunoassay,
 41:249
 prolactin, dyskinesia, 41:191
 prolactin, haloperidol, 41:191
 prolactin, homovanillic acid, 41:191
 prolactin, negative symptoms, 41:191
 prolactin, schizophrenia, 41:191, 41:249
 prolactin, side effects, 41:191
 psychosis, perphenazine, 41:147
 psychosis, symptom response, 41:147
 pupillometry, haloperidol, 43:287
 pupillometry, relapse, 43:287
 pupillometry, schizophrenia, 43:287
 relapse, haloperidol, 43:287
 relapse, pupillometry, 43:287
 relapse, schizophrenia, 43:287
 saccadic intrusions, clozapine, 41:25
 saccadic intrusions, eye movements, 41:25
 saccadic intrusions, schizophrenia, 41:25
 schizophrenia, abnormal-movement disorders,
 41:191
 schizophrenia, bioassay vs radioimmunoassay,
 41:249
 schizophrenia, ceruletide, 43:129
 schizophrenia, clozapine, 41:25
 schizophrenia, dyskinesia, 41:191
 schizophrenia, EEG, 42:129
 schizophrenia, electrodermal activity, 42:145
 schizophrenia, eye movements, 41:25
 schizophrenia, haloperidol, 41:191, 42:129,
 43:287
 schizophrenia, homovanillic acid, 41:191
 schizophrenia, negative symptoms, 41:191
 schizophrenia, neuroleptic malignant
 syndrome, 44:251
 schizophrenia, Parkinsonism, 41:9
 schizophrenia, positive symptoms, 42:145
 schizophrenia, prolactin, 41:191, 41:249
 schizophrenia, pupillometry, 43:287

Neuroleptics continued

schizophrenia, relapse, 43:287
 schizophrenia, saccadic intrusions, 41:25
 schizophrenia, side effects, 41:9, 41:191
 schizophrenia, side effects, 43:129
 schizophrenia, tardive dyskinesia, 43:129
 schizophrenia, temperature, 44:251
 schizophrenia, terguride, 41:9
 schizophrenia, treatment response, 42:129
 side effects, dyskinesia, 41:191
 side effects, haloperidol, 41:191
 side effects, homovanillic acid, 41:191
 side effects, negative symptoms, 41:191
 side effects, prolactin, 41:191
 side effects, schizophrenia, 41:9, 41:191,
 43:129
 side effects, terguride, 41:9
 symptom response, perphenazine, 41:147
 symptom response, psychosis, 41:147
 tardive dyskinesia, ceruletide, 43:129
 tardive dyskinesia, schizophrenia, 43:129
 temperature, neuroleptic malignant syndrome,
 44:251
 temperature, neuroleptics, 44:251
 temperature, schizophrenia, 44:251
 terguride, Parkinsonism, 41:9
 terguride, schizophrenia, 41:9
 terguride, side effects, 41:9
 treatment response, EEG, 42:129
 treatment response, haloperidol, 42:129
 treatment response, schizophrenia, 42:129
Neuropsychological tests
 Alzheimer's disease, diagnosis, 44:93
 attention, dramatic personality cluster, 42:283
 attention, memory, 42:283
 attention, personality disorder, 42:283
 catecholamines in urine, memory, 43:277
 catecholamines in urine, MHPG, 43:277
 catecholamines in urine, serotonin, 43:277
 catecholamines in urine, Tourette's syndrome,
 43:277
 color naming, frontal lobe, 41:137
 color naming, schizophrenia, 41:137
 color naming, Stroop task, 41:137
 diagnosis, Alzheimer's disease, 44:93
 dramatic personality cluster, attention, 42:283
 dramatic personality cluster, memory, 42:283
 eye movements, hand preference, 41:115
 eye movements, intelligence, 41:115
 eye movements, laterality, 41:115
 eye movements, normal men, 41:115
 eye movements, schizotypy, 41:115
 frontal lobe, color naming, 41:137

Neuropsychological tests continued

frontal lobe, schizophrenia, 41:137
 frontal lobe, Stroop task, 41:137
 hand preference, eye movements, 41:115
 hand preference, intelligence, 41:115
 hand preference, laterality, 41:115
 hand preference, normal men, 41:115
 hand preference, schizotypy, 41:115
 HIV, substance abuse, 41:163
 homovanillic acid, Tourette's syndrome, 43:277
 homovanillic acid, trace amines, 43:277
 intelligence, eye movements, 41:115
 intelligence, hand preference, 41:115
 intelligence, laterality, 41:115
 intelligence, normal men, 41:115
 intelligence, schizotypy, 41:115
 laterality, eye movements, 41:115
 laterality, hand preference, 41:115
 laterality, intelligence, 41:115
 laterality, normal men, 41:115
 laterality, schizotypy, 41:115
 memory, attention, 42:283
 memory, catecholamines in urine, 43:277
 memory, dramatic personality cluster, 42:283
 memory, MHPG, 43:277
 memory, personality disorder, 42:283
 memory, serotonin, 43:277
 memory, Tourette's syndrome, 43:277
 MHPG, catecholamines in urine, 43:277
 MHPG, memory, 43:277
 MHPG, serotonin, 43:277
 MHPG, Tourette's syndrome, 43:277
 normal men, eye movements, 41:115
 normal men, hand preference, 41:115
 normal men, intelligence, 41:115
 normal men, laterality, 41:115
 normal men, schizotypy, 41:115
 personality disorder, attention, 42:283
 personality disorder, memory, 42:283
 rehabilitation, schizophrenia, 43:223
 rehabilitation, social skills, 43:223
 schizophrenia, color naming, 41:137
 schizophrenia, frontal lobe, 41:137
 schizophrenia, rehabilitation, 43:223
 schizophrenia, social skills, 43:223
 schizophrenia, Stroop task, 41:137
 schizotypy, eye movements, 41:115
 schizotypy, hand preference, 41:115
 schizotypy, intelligence, 41:115
 schizotypy, laterality, 41:115
 schizotypy, normal men, 41:115
 serotonin, catecholamines in urine, 43:277
 serotonin, memory, 43:277

Neuropsychological tests continued

serotonin, MHPG, 43:277
 serotonin, Tourette's syndrome, 43:277
 social skills, rehabilitation, 43:223
 social skills, schizophrenia, 43:223
 Stroop task, color naming, 41:137
 Stroop task, frontal lobe, 41:137
 Stroop task, schizophrenia, 41:137
 substance abuse, HIV, 41:163
 Tourette's syndrome, catecholamines in urine, 43:277
 Tourette's syndrome, homovanillic acid, 43:277
 Tourette's syndrome, memory, 43:277
 Tourette's syndrome, MHPG, 43:277
 Tourette's syndrome, serotonin, 43:277
 Tourette's syndrome, trace amines, 43:277
 trace amines, homovanillic acid, 43:277
 trace amines, Tourette's syndrome, 43:277
Norepinephrine
 affective disorder, blood pressure, 43:199
 affective disorder, clonidine, 43:199
 affective disorder, cortisol, 43:31, 43:65
 affective disorder, desipramine, 43:65
 affective disorder, dopamine, 43:31
 affective disorder, epinephrine in urine, 43:31
 affective disorder, heart rate, 43:199
 affective disorder, MCPP, 43:65
 affective disorder, MHPG, 43:199
 affective disorder, panic disorder, 43:65
 affective disorder, serotonin, 43:65
 affective disorder, suicide, 43:31
 blood pressure, affective disorder, 43:199
 blood pressure, clonidine, 43:199
 blood pressure, heart rate, 43:199
 blood pressure, MHPG, 43:199
 clonidine, affective disorder, 43:199
 clonidine, blood pressure, 43:199
 clonidine, heart rate, 43:199
 clonidine, MHPG, 43:199
 cortisol, affective disorder, 43:31, 43:65
 cortisol, desipramine, 43:65
 cortisol, dopamine, 43:31
 cortisol, epinephrine in urine, 43:31
 cortisol, MCPP, 43:65
 cortisol, panic disorder, 43:65
 cortisol, serotonin, 43:65
 cortisol, suicide, 43:31
 desipramine, affective disorder, 43:65
 desipramine, cortisol, 43:65
 desipramine, MCPP, 43:65
 desipramine, panic disorder, 43:65
 desipramine, serotonin, 43:65
 diazepam, heart rate, 41:89

Norepinephrine continued

diazepam, normal men, 41:89
 diazepam, vagal tone, 41:89
 dopamine, affective disorder, 43:31
 dopamine, cortisol, 43:31
 dopamine, epinephrine in urine, 43:31
 dopamine, suicide, 43:31
 epinephrine in urine, affective disorder, 43:31
 epinephrine in urine, cortisol, 43:31
 epinephrine in urine, dopamine, 43:31
 epinephrine in urine, suicide, 43:31
 evoked potentials, MHPG, 44:21
 evoked potentials, schizophrenia, 44:21
 evoked potentials, sensory gating, 44:21
 heart rate, affective disorder, 43:199
 heart rate, blood pressure, 43:199
 heart rate, clonidine, 43:199
 heart rate, diazepam, 41:89
 heart rate, MHPG, 43:199
 heart rate, normal men, 41:89
 heart rate, vagal tone, 41:89
 MCPP, affective disorder, 43:65
 MCPP, cortisol, 43:65
 MCPP, desipramine, 43:65
 MCPP, panic disorder, 43:65
 MCPP, serotonin, 43:65
 MHPG, affective disorder, 43:199
 MHPG, blood pressure, 43:199
 MHPG, clonidine, 43:199
 MHPG, evoked potentials, 44:21
 MHPG, heart rate, 43:199
 MHPG, schizophrenia, 44:21
 MHPG, sensory gating, 44:21
 normal men, diazepam, 41:89
 normal men, heart rate, 41:89
 normal men, vagal tone, 41:89
 panic disorder, affective disorder, 43:65
 panic disorder, cortisol, 43:65
 panic disorder, desipramine, 43:65
 panic disorder, MCPP, 43:65
 panic disorder, serotonin, 43:65
 schizophrenia, evoked potentials, 44:21
 schizophrenia, MHPG, 44:21
 schizophrenia, sensory gating, 44:21
 sensory gating, evoked potentials, 44:21
 sensory gating, MHPG, 44:21
 sensory gating, schizophrenia, 44:21
 serotonin, affective disorder, 43:65
 serotonin, cortisol, 43:65
 serotonin, desipramine, 43:65
 serotonin, MCPP, 43:65
 serotonin, panic disorder, 43:65
 suicide, affective disorder, 43:31
 suicide, cortisol, 43:31

Norepinephrine continued

suicide, dopamine, 43:31
 suicide, epinephrine in urine, 43:31
 vagal tone, diazepam, 41:89
 vagal tone, heart rate, 41:89
 vagal tone, normal men, 41:89
Obsessive-compulsive disorder
 affective disorder, amino acids in plasma, 44:91
 affective disorder, comorbidity, 42:111
 affective disorder, genetics, 42:111
 affective disorder, tryptophan, 44:91
 amino acids in plasma, affective disorder, 44:91
 amino acids in plasma, tryptophan, 44:91
 anxiety, depressed mood, 42:267
 anxiety, dystonia, 42:267
 anxiety, torticollis, 42:267
 comorbidity, affective disorder, 42:111
 comorbidity, genetics, 42:111
 comorbidity, panic disorder, 42:171
 cortisol, melatonin, 44:217
 depressed mood, anxiety, 42:267
 depressed mood, dystonia, 42:267
 depressed mood, torticollis, 42:267
 dystonia, anxiety, 42:267
 dystonia, depressed mood, 42:267
 dystonia, torticollis, 42:267
 eyemovements, smooth pursuit, 42:1
 fenfluramine, homovanillic acid, 42:185
 fenfluramine, prolactin, 42:81
 fenfluramine, serotonin, 42:81
 fenfluramine, sex differences, 42:81
 genetics, affective disorder, 42:111
 genetics, comorbidity, 42:111
 5-HIAA, indole-3-acetic acid, 41:267
 5-HIAA, serotonin, 41:267
 5-HIAA, Tourette's syndrome, 41:267
 5-HIAA, tryptamine, 41:267
 homovanillic acid, fenfluramine, 42:185
 imipramine, platelet imipramine binding, 42:41
 imipramine, serotonin, 42:41
 imipramine, sulfotransferase in platelets, 42:41
 indole-3-acetic acid, 5-HIAA, 41:267
 indole-3-acetic acid, serotonin, 41:267
 indole-3-acetic acid, Tourette's syndrome, 41:267
 indole-3-acetic acid, tryptamine, 41:267
 melatonin, cortisol, 44:217
 panic disorder, comorbidity, 42:171
 platelet imipramine binding, serotonin, 42:41
 platelet imipramine binding, sulfotransferase in platelets, 42:41

Obsessive-compulsive disorder continued

- prolactin, fenfluramine, 42:81
- prolactin, serotonin, 42:81
- prolactin, sex differences, 42:81
- reliability and validity, Symptom Checklist-90, 41:37
- serotonin, fenfluramine, 42:81
- serotonin, 5-HIAA, 41:267
- serotonin, imipramine, 42:41
- serotonin, indole-3-acetic acid, 41:267
- serotonin, platelet imipramine binding, 42:41
- serotonin, prolactin, 42:81
- serotonin, sex differences, 42:81
- serotonin, sulfotransferase in platelets, 42:41
- serotonin, Tourette's syndrome, 41:267
- serotonin, tryptamine, 41:267
- sex differences, fenfluramine, 42:81
- sex differences, prolactin, 42:81
- sex differences, serotonin, 42:81
- smooth pursuit, eye movements, 42:1
- sulfotransferase in platelets, imipramine, 42:41
- sulfotransferase in platelets, platelet imipramine binding, 42:41
- sulfotransferase in platelets, serotonin, 42:41
- Symptom Checklist-90, reliability and validity, 41:37
- torticollis, anxiety, 42:267
- torticollis, depressed mood, 42:267
- torticollis, dystonia, 42:267
- Tourette's syndrome, 5-HIAA, 41:267
- Tourette's syndrome, indole-3-acetic acid, 41:267
- Tourette's syndrome, serotonin, 41:267
- Tourette's syndrome, tryptamine, 41:267
- tryptamine, 5-HIAA, 41:267
- tryptamine, indole-3-acetic acid, 41:267
- tryptamine, serotonin, 41:267
- tryptamine, Tourette's syndrome, 41:267
- tryptophan, affective disorder, 44:91
- tryptophan, amino acids in plasma, 44:91
- Parkinsonism**
- neuroleptics, schizophrenia, 41:9
- neuroleptics, side effects, 41:9
- neuroleptics, terguride, 41:9
- schizophrenia, neuroleptics, 41:9
- schizophrenia, side effects, 41:9
- schizophrenia, terguride, 41:9
- side effects, neuroleptics, 41:9
- side effects, schizophrenia, 41:9
- side effects, terguride, 41:9
- terguride, neuroleptics, 41:9
- terguride, schizophrenia, 41:9

Perphenazine

- neuroleptics, psychosis, 41:147
- neuroleptics, symptom response, 41:147
- psychosis, neuroleptics, 41:147
- psychosis, symptom response, 41:147
- symptom response, neuroleptics, 41:147
- symptom response, psychosis, 41:147
- Prolactin**
- abnormal-movement disorders, dyskinesia, 41:191
- abnormal-movement disorders, haloperidol, 41:191
- abnormal-movement disorders, homovanillic acid, 41:191
- abnormal-movement disorders, negative symptoms, 41:191
- abnormal-movement disorders, neuroleptics, 41:191
- abnormal-movement disorders, schizophrenia, 41:191
- abnormal-movement disorders, side effects, 41:191
- abstinence, carbidopa treatment, 43:77
- abstinence, cocaine, 43:77
- abstinence, growth hormone, 43:77
- abstinence, homovanillic acid, 43:77
- abstinence, MHPG, 43:77
- abstinence, substance abuse, 43:77
- ACTH, MCPP, 43:1
- ACTH, schizophrenia, 43:1
- ACTH, serotonin, 43:1
- ACTH, temperature of body, 43:1
- affective disorder, cortisol, 43:137
- affective disorder, fenfluramine, 43:137
- affective disorder, melancholia, 43:137
- affective disorder, serotonin, 43:137
- aggression, childhood disorders, 43:263
- aggression, cortisol, 43:263
- aggression, disruptive behavior disorder, 43:263
- aggression, fenfluramine, 43:263
- aggression, serotonin, 43:263
- alcoholism, thyroxine, 43:121
- alcoholism, TRH, 43:121
- alcoholism, triiodothyronine, 43:121
- alcoholism, TSH, 43:121
- attention deficit disorder, cortisol, 42:65
- attention deficit disorder, fenfluramine challenge, 42:65
- bioassay vs. radioimmunoassay, neuroleptics, 41:249
- bioassay vs. radioimmunoassay, schizophrenia, 41:249
- carbidopa treatment, abstinence, 43:77

Prolactin continued

carbidopa treatment, cocaine, 43:77
 carbidopa treatment, growth hormone, 43:77
 carbidopa treatment, homovanillic acid, 43:77
 carbidopa treatment, MHPG, 43:77
 carbidopa treatment, substance abuse, 43:77
 childhood disorders, aggression, 43:263
 childhood disorders, attention deficit disorder, 42:65
 childhood disorders, cortisol, 42:65
 childhood disorders, cortisol, 43:263
 childhood disorders, disruptive behavior disorder, 42:65, 43:263
 childhood disorders, fenfluramine, 43:263
 childhood disorders, fenfluramine challenge, 42:65
 childhood disorders, serotonin, 43:263
 circadian rhythms, cortisol, 43:161
 circadian rhythms, melatonin, 43:161
 circadian rhythms, platelet serotonin uptake, 43:161
 circadian rhythms, serotonin, 43:161
 cocaine, abstinence, 43:77
 cocaine, carbidopa treatment, 43:77
 cocaine, growth hormone, 43:77
 cocaine, homovanillic acid, 43:77
 cocaine, MHPG, 43:77
 cocaine, substance abuse, 43:77
 cortisol, affective disorder, 43:137
 cortisol, aggression, 43:263
 cortisol, attention deficit disorder, 42:65
 cortisol, childhood disorders, 42:65, 43:263
 cortisol, circadian rhythms, 43:161
 cortisol, disruptive behavior disorder, 42:65, 43:263
 cortisol, fenfluramine, 43:137, 43:263
 cortisol, fenfluramine challenge, 42:65
 cortisol, melancholia, 43:137
 cortisol, melatonin, 43:161
 cortisol, platelet serotonin uptake, 43:161
 cortisol, serotonin, 43:137, 43:161, 43:263
 disruptive behavior disorder, aggression, 43:263
 disruptive behavior disorder, childhood disorders, 43:263
 disruptive behavior disorder, cortisol, 42:65, 43:263
 disruptive behavior disorder, fenfluramine, 42:65, 43:263
 disruptive behavior disorder, serotonin, 43:263
 domperidone, dopamine, 42:159
 domperidone, growth hormone, 42:159
 domperidone, schizophrenia, 42:159

Prolactin continued

dopamine, domperidone, 42:159
 dopamine, growth hormone, 42:159
 dopamine, schizophrenia, 42:159
 dyskinesia, haloperidol, 41:191
 dyskinesia, homovanillic acid, 41:191
 dyskinesia, negative symptoms, 41:191
 dyskinesia, neuroleptics, 41:191
 dyskinesia, schizophrenia, 41:191
 fenfluramine, affective disorder, 43:137
 fenfluramine, aggression, 43:263
 fenfluramine challenge, attention deficit disorder, 42:65
 fenfluramine challenge, childhood disorders, 42:65
 fenfluramine challenge, cortisol, 42:65
 fenfluramine challenge, disruptive behavior disorder, 42:65
 fenfluramine, childhood disorders, 43:263
 fenfluramine, cortisol, 43:137, 43:263
 fenfluramine, disruptive behavior disorder, 43:263
 fenfluramine, melancholia, 43:137
 fenfluramine, obsessive-compulsive disorder, 42:81
 fenfluramine, serotonin, 42:81, 43:137, 43:263
 fenfluramine, sex differences, 42:81
 growth hormone, abstinence, 43:77
 growth hormone, carbidopa treatment, 43:77
 growth hormone, cocaine, 43:77
 growth hormone, domperidone, 42:159
 growth hormone, dopamine, 42:159
 growth hormone, homovanillic acid, 43:77
 growth hormone, MHPG, 43:77
 growth hormone, schizophrenia, 42:159
 growth hormone, substance abuse, 43:77
 haloperidol, abnormal-movement disorders, 41:191
 haloperidol, dyskinesia, 41:191
 haloperidol, homovanillic acid, 41:191
 haloperidol, negative symptoms, 41:191
 haloperidol, schizophrenia, 41:191
 haloperidol, side effects, 41:191
 homovanillic acid, abnormal-movement disorders, 41:191
 homovanillic acid, abstinence, 43:77
 homovanillic acid, carbidopa treatment, 43:77
 homovanillic acid, cocaine, 43:77
 homovanillic acid, dyskinesia, 41:191
 homovanillic acid, growth hormone, 43:77
 homovanillic acid, haloperidol, 41:191
 homovanillic acid, MHPG, 43:77
 homovanillic acid, negative symptoms, 41:191
 homovanillic acid, neuroleptics, 41:191

Prolactin continued

homovanillic acid, schizophrenia, 41:191
 homovanillic acid, side effects, 41:191
 homovanillic acid, substance abuse, 43:77
 MCPP, ACTH, 43:1
 MCPP, schizophrenia, 43:1
 MCPP, serotonin, 43:1
 MCPP, temperature of body, 43:1
 melancholia, affective disorder, 43:137
 melancholia, cortisol, 43:137
 melancholia, fenfluramine, 43:137
 melancholia, serotonin, 43:137
 melatonin, circadian rhythms, 43:161
 melatonin, cortisol, 43:161
 melatonin, platelet serotonin uptake, 43:161
 melatonin, serotonin, 43:161
 MHPG, abstinence, 43:77
 MHPG, carbidopa treatment, 43:77
 MHPG, cocaine, 43:77
 MHPG, growth hormone, 43:77
 MHPG, homovanillic acid, 43:77
 MHPG, substance abuse, 43:77
 negative symptoms, abnormal-movement disorders, 41:191
 negative symptoms, dyskinesia, 41:191
 negative symptoms, haloperidol, 41:191
 negative symptoms, homovanillic acid, 41:191
 negative symptoms, neuroleptics, 41:191
 negative symptoms, schizophrenia, 41:191
 negative symptoms, side effects, 41:191
 neuroleptics, abnormal-movement disorders, 41:191
 neuroleptics, bioassay vs. radioimmunoassay, 41:249
 neuroleptics, dyskinesia, 41:191
 neuroleptics, haloperidol, 41:191
 neuroleptics, homovanillic acid, 41:191
 neuroleptics, negative symptoms, 41:191
 neuroleptics, schizophrenia, 41:191, 41:249
 neuroleptics, side effects, 41:191
 obsessive-compulsive disorder, fenfluramine, 42:81
 obsessive-compulsive disorder, serotonin, 42:81
 obsessive-compulsive disorder, sex differences, 42:81
 platelet serotonin uptake, circadian rhythms, 43:161
 platelet serotonin uptake, cortisol, 43:161
 platelet serotonin uptake, melatonin, 43:161
 schizophrenia, abnormal-movement disorders, 41:191
 schizophrenia, ACTH, 43:1
 schizophrenia, bioassay vs. radioimmunoassay, 41:249

Prolactin continued

schizophrenia, domperidone, 42:159
 schizophrenia, dopamine, 42:159
 schizophrenia, dyskinesia, 41:191
 schizophrenia, growth hormone, 42:159
 schizophrenia, haloperidol, 41:191
 schizophrenia, homovanillic acid, 41:191
 schizophrenia, MCPP, 43:1
 schizophrenia, negative symptoms, 41:191
 schizophrenia, neuroleptics, 41:191, 41:249
 schizophrenia, serotonin, 43:1
 schizophrenia, side effects, 41:191
 schizophrenia, temperature of body, 43:1
 serotonin, ACTH, 43:1
 serotonin, affective disorder, 43:137
 serotonin, aggression, 43:263
 serotonin, childhood disorders, 43:263
 serotonin, circadian rhythms, 43:161
 serotonin, cortisol, 43:137, 43:161, 43:263
 serotonin, disruptive behavior disorder, 43:263
 serotonin, fenfluramine, 42:81, 43:137, 43:263
 serotonin, MCPP, 43:1
 serotonin, melancholia, 43:137
 serotonin, melatonin, 43:161
 serotonin, obsessive-compulsive disorder, 42:81
 serotonin, platelet uptake, 43:161
 serotonin, schizophrenia, 43:1
 serotonin, sex differences, 42:81
 serotonin, temperature of body, 43:1
 sex differences, fenfluramine, 42:81
 sex differences, obsessive-compulsive disorder, 42:81
 sex differences, serotonin, 42:81
 side effects, haloperidol, 41:191
 side effects, homovanillic acid, 41:191
 side effects, negative symptoms, 41:191
 side effects, neuroleptics, 41:191
 side effects, schizophrenia, 41:191
 substance abuse, abstinence, 43:77
 substance abuse, carbidopa treatment, 43:77
 substance abuse, cocaine, 43:77
 substance abuse, growth hormone, 43:77
 substance abuse, homovanillic acid, 43:77
 substance abuse, MHPG, 43:77
 temperature of body, ACTH, 43:1
 temperature of body, MCPP, 43:1
 temperature of body, schizophrenia, 43:1
 temperature of body, serotonin, 43:1
 thyroxine, alcoholism, 43:121
 thyroxine, TRH, 43:121
 thyroxine, triiodothyronine, 43:121
 thyroxine, TSH, 43:121
 TRH, alcoholism, 43:121
 TRH, thyroxine, 43:121

Prolactin continued

- TRH, triiodothyronine, 43:121
- TRH, TSH, 43:121
- triiodothyronine, alcoholism, 43:121
- triiodothyronine, thyroxine, 43:121
- triiodothyronine, TRH, 43:121
- triiodothyronine, TSH, 43:121
- TSH, alcoholism, 43:121
- TSH, thyroxine, 43:121
- TSH, TRH, 43:121
- TSH, triiodothyronine, 43:121

Schizophrenia

- abnormal-movement disorders, haloperidol, 41:191
- abnormal-movement disorders, homovanillic acid, 41:191
- abnormal-movement disorders, negative symptoms, 41:191
- abnormal-movement disorders, neuroleptics, 41:191
- abnormal-movement disorders, prolactin, 41:191
- ACTH, MCPP, 43:1
- ACTH, prolactin, 43:1
- ACTH, serotonin, 43:1
- ACTH, temperature of body, 43:1
- acute psychosis, symptom response, 41:147
- affective disorder, cortisol, 44:1
- affective disorder, eye movements, 43:93
- affective disorder, monoamine oxidase, 44:1
- affective disorder, paranoid subtype, 43:93
- affective disorder, saccades, 43:93
- age of onset, diagnostic subtypes, 41:107
- age of onset, genetics, 41:107
- age of onset, growth hormone at night, 41:155
- age of onset, siblings, 41:107
- attention, backward masking, 44:203
- attention, genetics, 44:125
- attention, high-risk study, 44:125
- attention, laterality, 43:87
- attention, negative symptoms, 43:87
- attention, reaction time, 44:125, 43:87
- backward masking, attention, 44:203
- basal ganglia, GABA uptake site, 42:273
- basal ganglia, glutamate uptake site, 42:273
- basal ganglia, post-mortem brain, 42:273
- bioassay vs. radioimmunoassay, neuroleptics, 41:249
- bioassay vs. radioimmunoassay, prolactin, 41:249
- calcium binding protein, chromogranin A, 42:53
- calcium binding protein, polysomnography, 42:53

Schizophrenia continued

- calcium binding protein, sleep, 42:53
- cerebrospinal fluid, CRH, 43:13
- cerebrospinal fluid, peptides, 43:13
- cerebrospinal fluid, somatostatin, 43:13
- cerebrospinal fluid, TRH, 43:13
- ceruletide, neuroleptics, 43:129
- ceruletide, side effects, 43:129
- ceruletide, tardive dyskinesia, 43:129
- cholinesterase isozymes, polysomnography, 43:23
- cholinesterase isozymes, sleep, 43:23
- chromogranin A, calcium binding protein, 42:53
- chromogranin A, polysomnography, 42:53
- chromogranin A, sleep, 42:53
- chromosome 5, genetics, 44:171
- circadian rhythm, growth hormone, 41:155
- circadian rhythm, sleep, 41:155
- clozapine, electroencephalography, 44:107
- clozapine, epileptic seizures, 44:107
- clozapine, eye movements, 41:25
- clozapine, neuroleptics, 41:25
- clozapine, saccadic intrusions, 41:25
- color naming, frontal lobe, 41:137
- color naming, neuropsychological tests, 41:137
- color naming, Stroop task, 41:137
- computed tomography, cortical atrophy, 44:55
- computed tomography, negative symptoms, 44:55
- computed tomography, subtype diagnosis, 42:209
- computed tomography, symptomatology, 42:209
- computed tomography, ventricle-brain ratio, 44:55
- computed tomography, ventricular size, 42:209
- content analysis, expressed emotion, 41:275
- content analysis, family interview, 41:275
- content analysis, relapse prediction, 41:275
- cortical atrophy, computed tomography, 44:55
- cortical atrophy, negative symptoms, 44:55
- cortical atrophy, ventricle-brain ratio, 44:55
- cortisol, affective disorder, 44:1
- cortisol, monoamine oxidase, 44:1
- CRH, cerebrospinal fluid, 43:13
- CRH, peptides, 43:13
- CRH, somatostatin, 43:13
- CRH, TRH, 43:13
- CSF, neuron-specific enolase, 43:187
- delusional state, dopamine, 41:17
- delusional state, platelets, 41:17
- deprenyl, MAO inhibitors, 42:189
- deprenyl, negative symptoms, 42:189

Schizophrenia continued

depression, mood state assessment, 42:199
 depression, self vs. observer ratings, 42:199
 diagnostic subtypes, age of onset, 41:107
 diagnostic subtypes, genetics, 41:107
 diagnostic subtypes, siblings, 41:107
 domperidone, dopamine, 42:159
 domperidone, growth hormone, 42:159
 domperidone, prolactin, 42:159
 dopamine, delusional state, 41:17
 dopamine, domperidone, 42:159
 dopamine, growth hormone, 42:159
 dopamine, platelets, 41:17
 dopamine, prolactin, 42:159
 dyskinesia, haloperidol, 41:191
 dyskinesia, homovanillic acid, 41:191
 dyskinesia, negative symptoms, 41:191
 dyskinesia, neuroleptics, 41:191
 dyskinesia, prolactin, 41:191
 EEG, haloperidol, 42:129
 EEG, neuroleptics, 42:129
 EEG, treatment response, 42:129
 electrodermal activity, neuroleptics, 42:145
 electrodermal activity, positive symptoms, 42:145
 electroencephalography, clozapine, 44:107
 electroencephalography, epileptic seizures, 44:107
 emotion, facial affective discrimination, 42:253
 emotion, symptom severity, 42:253
 enolase, neurodegeneration, 43:187
 entorhinal cortex, post-mortem study, 44:79
 epileptic seizures, clozapine, 44:107
 epileptic seizures, electroencephalography, 44:107
 evoked potentials, eye movements, 41:227
 evoked potentials, MHPG, 44:21
 evoked potentials, norepinephrine, 44:21
 evoked potentials, sensory gating, 44:21
 expressed emotion, content analysis, 41:275
 expressed emotion, family interview, 41:275
 expressed emotion, relapse prediction, 41:275
 eye movements, affective disorder, 43:93
 eye movements, clozapine, 41:25
 eye movements, evoked potentials, 41:227
 eye movements, neuroleptics, 41:25
 eye movements, paranoid subtype, 43:93
 eye movements, saccades, 43:93
 eye movements, saccadic intrusions, 41:25
 facial affective discrimination, emotion, 42:253
 facial affective discrimination, symptom severity, 42:253

Schizophrenia continued

factor analysis, negative symptoms, 44:153
 factor analysis, thought disorder, 44:141
 family interview, content analysis, 41:275
 family interview, expressed emotion, 41:275
 family interview, relapse prediction, 41:275
 frontal lobe, color naming, 41:137
 frontal lobe, neuropsychological tests, 41:137
 frontal lobe, Stroop task, 41:137
 GABA uptake site, basal ganglia, 42:273
 GABA uptake site, glutamate uptake site, 42:273
 GABA uptake site, post-mortem brain, 42:273
 genetics, age of onset, 41:107
 genetics, attention, 44:125
 genetics, chromosome 5, 44:171
 genetics, diagnostic subtypes, 41:107
 genetics, high-risk study, 44:125
 genetics, HLA, 41:99
 genetics, linkage, 41:99
 genetics, multiplex families, 41:99
 genetics, reaction time, 44:125
 genetics, siblings, 41:107
 glutamate uptake site, basal ganglia, 42:273
 glutamate uptake site, GABA uptake site, 42:273
 glutamate uptake site, post-mortem brain, 42:273
 growth hormone at night, age of onset, 41:155
 growth hormone, circadian rhythm, 41:155
 growth hormone, domperidone, 42:159
 growth hormone, dopamine, 42:159
 growth hormone, prolactin, 42:159
 growth hormone, sleep, 41:155
 haloperidol, abnormal-movement disorders, 41:191
 haloperidol, dyskinesia, 41:191
 haloperidol, EEG, 42:129
 haloperidol, homovanillic acid, 41:191
 haloperidol, negative symptoms, 41:191
 haloperidol, prolactin, 41:191
 haloperidol, pupillometry, 43:287
 haloperidol, relapse, 43:287
 haloperidol, side effects, 41:191
 haloperidol, treatment response, 42:129
 high-risk study, attention, 44:125
 high-risk study, genetics, 44:125
 high-risk study, reaction time, 44:125
 HLA, genetics, 41:99
 HLA, linkage, 41:99
 HLA, multiplex families, 41:99
 homovanillic acid, abnormal-movement disorders, 41:191
 homovanillic acid, dyskinesia, 41:191

Schizophrenia continued

homovanillic acid, haloperidol, 41:191
 homovanillic acid, negative symptoms, 41:191
 homovanillic acid, neuroleptics, 41:191
 homovanillic acid, prolactin, 41:191
 homovanillic acid, side effects, 41:191
 immunology, interleukin-2, 44:113
 immunology, neopterin, 42:121
 immunology, symptom severity, 42:121
 interleukin-2, immunology, 44:113
 laterality, attention, 43:87
 laterality, negative symptoms, 43:87
 laterality, reaction time, 43:87
 linkage, genetics, 41:99
 linkage, HLA, 41:99
 linkage, multiplex families, 41:99
 MAO inhibitors, deprenyl, 42:189
 MAO inhibitors, negative symptoms, 42:189
 MCPP, ACTH, 43:1
 MCPP, prolactin, 43:1
 MCPP, serotonin, 43:1
 MCPP, temperature of body, 43:1
 MHPG, evoked potentials, 44:21
 MHPG, norepinephrine, 44:21
 MHPG, sensory gating, 44:21
 monoamine oxidase, affective disorder, 44:1
 monoamine oxidase, cortisol, 44:1
 mood state assessment, depression, 42:199
 mood state assessment, self vs. observer ratings, 42:199
 multiplex families, genetics, 41:99
 multiplex families, HLA, 41:99
 multiplex families, linkage, 41:99
 negative symptoms, abnormal-movement disorders, 41:191
 negative symptoms, attention, 43:87
 negative symptoms, computed tomography, 44:55
 negative symptoms, cortical atrophy, 44:55
 negative symptoms, deprenyl, 42:189
 negative symptoms, dyskinesia, 41:191
 negative symptoms, factor analysis, 44:153
 negative symptoms, haloperidol, 41:191
 negative symptoms, homovanillic acid, 41:191
 negative symptoms, laterality, 43:87
 negative symptoms, MAO inhibitors, 42:189
 negative symptoms, neuroleptics, 41:191
 negative symptoms, outcome, 43:215
 negative symptoms, prolactin, 41:191
 negative symptoms, reaction time, 43:87
 negative symptoms, side effects, 41:191
 negative symptoms, ventricle-brain ratio, 44:55
 neopterin, immunology, 42:121
 neopterin, symptom severity, 42:121

Schizophrenia continued

neurodegeneration, enolase, 43:187
 neuroleptic malignant syndrome, neuroleptics, 44:251
 neuroleptic malignant syndrome, temperature, 44:251
 neuroleptics, abnormal-movement disorders, 41:191
 neuroleptics, bioassay vs. radioimmunoassay, 41:249
 neuroleptics, ceruletide, 43:129
 neuroleptics, clozapine, 41:25
 neuroleptics, dyskinesia, 41:191
 neuroleptics, EEG, 42:129
 neuroleptics, electrodermal activity, 42:145
 neuroleptics, eye movements, 41:25
 neuroleptics, homovanillic acid, 41:191
 neuroleptics, negative symptoms, 41:191
 neuroleptics, neuroleptic malignant syndrome, 44:251
 neuroleptics, Parkinsonism, 41:9
 neuroleptics, positive symptoms, 42:145
 neuroleptics, prolactin, 41:191, 41:249
 neuroleptics, pupillometry, 43:287
 neuroleptics, relapse, 43:287
 neuroleptics, saccadic intrusions, 41:25
 neuroleptics, side effects, 41:9, 41:191, 43:129
 neuroleptics, tardive dyskinesia, 43:129
 neuroleptics, temperature, 44:251
 neuroleptics, terguride, 41:9
 neuroleptics, treatment response, 42:129
 neuron-specific enolase, CSF, 43:187
 neuropsychological tests, color naming, 41:137
 neuropsychological tests, frontal lobe, 41:137
 neuropsychological tests, rehabilitation, 43:223
 neuropsychological tests, social skills, 43:223
 neuropsychological tests, Stroop task, 41:137
 norepinephrine, evoked potentials, 44:21
 norepinephrine, MHPG, 44:21
 norepinephrine, sensory gating, 44:21
 outcome, negative symptoms, 43:215
 paranoid subtype, affective disorder, 43:93
 paranoid subtype, eye movements, 43:93
 paranoid subtype, saccades, 43:93
 Parkinsonism, neuroleptics, 41:9
 Parkinsonism, side effects, 41:9
 Parkinsonism, terguride, 41:9
 peptides, cerebrospinal fluid, 43:13
 peptides, CRH, 43:13
 peptides, somatostatin, 43:13
 peptides, TRH, 43:13
 platelets, delusional state, 41:17

Schizophrenia continued

platelets, dopamine, 41:17
 polysomnography, calcium binding protein, 42:53
 polysomnography, cholinesterase isozymes, 43:23
 polysomnography, chromogranin A, 42:53
 polysomnography, sleep, 42:53, 43:23
 positive symptoms, electrodermal activity, 42:145
 positive symptoms, neuroleptics, 42:145
 post-mortem brain, basal ganglia, 42:273
 post-mortem brain, GABA uptake site, 42:273
 post-mortem brain, glutamate uptake site, 42:273
 post-mortem study, entorhinal cortex, 44:79
 prolactin, abnormal-movement disorders, 41:191
 prolactin, ACTH, 43:1
 prolactin, bioassay vs. radioimmunoassay, 41:249
 prolactin, domperidone, 42:159
 prolactin, dopamine, 42:159
 prolactin, dyskinesia, 41:191
 prolactin, growth hormone, 42:159
 prolactin, haloperidol, 41:191
 prolactin, homovanillic acid, 41:191
 prolactin, MCPP, 43:1
 prolactin, negative symptoms, 41:191
 prolactin, neuroleptics, 41:191, 41:249
 prolactin, serotonin, 43:1
 prolactin, side effects, 41:191
 prolactin, temperature of body, 43:1
 pupillometry, haloperidol, 43:287
 pupillometry, neuroleptics, 43:287
 pupillometry, relapse, 43:287
 reaction time, attention, 43:87, 44:125
 reaction time, genetics, 44:125
 reaction time, high-risk study, 44:125
 reactiontime, laterality, 43:87
 reactiontime, negative symptoms, 43:87
 rehabilitation, neuropsychological tests, 43:223
 rehabilitation, social skills, 43:223
 relapse, haloperidol, 43:287
 relapse, neuroleptics, 43:287
 relapse prediction, content analysis, 41:275
 relapse prediction, expressed emotion, 41:275
 relapse prediction, family interview, 41:275
 relapse, pupillometry, 43:287
 saccades, affective disorder, 43:93
 saccades, eye movements, 43:93
 saccades, paranoid subtype, 43:93
 saccadic intrusions, clozapine, 41:25
 saccadic intrusions, eye movements, 41:25

Schizophrenia continued

saccadic intrusions, neuroleptics, 41:25
 self vs. observer ratings, depression, 42:199
 self vs. observer ratings, mood state assessment, 42:199
 sensory gating, evoked potentials, 44:21
 sensory gating, MHPG, 44:21
 sensory gating, norepinephrine, 44:21
 serotonin, ACTH, 43:1
 serotonin, MCPP, 43:1
 serotonin, prolactin, 43:1
 serotonin, temperature of body, 43:1
 siblings, age of onset, 41:107
 siblings, diagnostic subtypes, 41:107
 siblings, genetics, 41:107
 side effects, abnormal-movement disorders, 41:191
 side effects, ceruletide, 43:129
 side effects, dyskinesia, 41:191
 side effects, haloperidol, 41:191
 side effects, homovanillic acid, 41:191
 side effects, negative symptoms, 41:191
 side effects, neuroleptics, 41:9, 41:191, 43:129
 side effects, Parkinsonism, 41:9
 side effects, prolactin, 41:191
 side effects, tardive dyskinesia, 43:129
 side effects, terguride, 41:9
 sleep, calcium binding protein, 42:53
 sleep, cholinesterase isozymes, 43:23
 sleep, chromogranin A, 42:53
 sleep, circadian rhythm, 41:155
 sleep, growth hormone, 41:155
 sleep, polysomnography, 42:53, 43:23
 social skills, neuropsychological tests, 43:223
 social skills, rehabilitation, 43:223
 somatostatin, cerebrospinal fluid, 43:13
 somatostatin, CRH, 43:13
 somatostatin, peptides, 43:13
 somatostatin, TRH, 43:13
 Strooptask, color naming, 41:137
 Strooptask, frontal lobe, 41:137
 subtype diagnosis, computed tomography, 42:209
 subtype diagnosis, symptomatology, 42:209
 subtype diagnosis, ventricular size, 42:209
 symptom response, acute psychosis, 41:147
 symptom severity, emotion, 42:253
 symptom severity, facial affective discrimination, 42:253
 symptom severity, immunology, 42:121
 symptom severity, neopterin, 42:121
 symptomatology, computed tomography, 42:209
 symptomatology, subtype diagnosis, 42:209
 symptomatology, ventricular size, 42:209
 tardive dyskinesia, ceruletide, 43:129

Schizophrenia continued

tardive dyskinesia, neuroleptics, 43:129
 temperature, neuroleptic malignant syndrome, 44:251

temperature, neuroleptics, 44:251
 temperature of body, ACTH, 43:1
 temperature of body, MCPP, 43:1
 temperature of body, prolactin, 43:1
 temperature of body, serotonin, 43:1
 terguride, neuroleptics, 41:9
 terguride, Parkinsonism, 41:9
 terguride, side effects, 41:9
 thought disorder, factor analysis, 44:141
 treatment response, EEG, 42:129
 treatment response, haloperidol, 42:129
 treatment response, neuroleptics, 42:129
 TRH, cerebrospinal fluid, 43:13
 TRH, CRH, 43:13
 TRH, peptides, 43:13
 TRH, somatostatin, 43:13
 ventricle-brain ratio, computed tomography, 44:55
 ventricle-brain ratio, cortical atrophy, 44:55
 ventricle-brain ratio, negative symptoms, 44:55
 ventricular size, computed tomography, 42:209
 ventricular size, subtype diagnosis, 42:209
 ventricular size, symptomatology, 42:209

Schizotypy

assortative mating, genetics, 41:283
 eye movements, hand preference, 41:115
 eye movements, intelligence, 41:115
 eye movements, laterality, 41:115
 eye movements, neuropsychological tests, 41:115
 eye movements, normal men, 41:115
 genetics, assortative mating, 41:283
 hand preference, eye movements, 41:115
 hand preference, intelligence, 41:115
 hand preference, laterality, 41:115
 hand preference, neuropsychological tests, 41:115
 hand preference, normal men, 41:115
 intelligence, eye movements, 41:115
 intelligence, hand preference, 41:115
 intelligence, laterality, 41:115
 intelligence, neuropsychological tests, 41:115
 intelligence, normal men, 41:115
 laterality, eye movements, 41:115
 laterality, hand preference, 41:115
 laterality, intelligence, 41:115
 laterality, neuropsychological tests, 41:115
 laterality, normal men, 41:115
 neuropsychological tests, eye movements, 41:115

Schizotypy continued

neuropsychological tests, hand preference, 41:115
 neuropsychological tests, intelligence, 41:115
 neuropsychological tests, laterality, 41:115
 neuropsychological tests, normal men, 41:115
 normal men, eye movements, 41:115
 normal men, hand preference, 41:115
 normal men, intelligence, 41:115
 normal men, laterality, 41:115
 normal men, neuropsychological tests, 41:115
Serotonin
 ACTH, MCPP, 43:1
 ACTH, prolactin, 43:1
 ACTH, schizophrenia, 43:1
 ACTH, temperature of body, 43:1
 affective disorder, cortisol, 43:65, 43:137
 affective disorder, desipramine, 43:65
 affective disorder, fenfluramine, 43:137
 affective disorder, MCPP, 43:65
 affective disorder, melancholia, 43:137
 affective disorder, norepinephrine, 43:65
 affective disorder, panic disorder, 43:65
 affective disorder, prolactin, 43:137
 aggression, childhood disorders, 43:263
 aggression, cortisol, 43:263
 aggression, disruptive behavior disorder, 43:263
 aggression, fenfluramine, 43:263
 aggression, prolactin, 43:263
 catecholamines in urine, memory, 43:277
 catecholamines in urine, MHPG, 43:277
 catecholamines in urine, neuropsychological tasks, 43:277
 catecholamines in urine, Tourette's syndrome, 43:277
 childhood disorders, aggression, 43:263
 childhood disorders, cortisol, 43:263
 childhood disorders, disruptive behavior disorder, 43:263
 childhood disorders, fenfluramine, 43:263
 childhood disorders, prolactin, 43:263
 circadian rhythms, cortisol, 43:161
 circadian rhythms, melatonin, 43:161
 circadian rhythms, platelet serotonin uptake, 43:161
 circadian rhythms, prolactin, 43:161
 cortisol, affective disorder, 43:137
 cortisol, affective disorder, 43:65
 cortisol, aggression, 43:263
 cortisol, childhood disorders, 43:263
 cortisol, circadian rhythms, 43:161
 cortisol, desipramine, 43:65
 cortisol, disruptive behavior disorder, 43:263

Serotonin continued

cortisol, fenfluramine, 43:137, 43:263
 cortisol, MCPP, 43:65
 cortisol, melancholia, 43:137
 cortisol, melatonin, 43:161
 cortisol, norepinephrine, 43:65
 cortisol, panic disorder, 43:65
 cortisol, platelet serotonin uptake, 43:161
 cortisol, prolactin, 43:137, 43:161, 43:263
 desipramine, affective disorder, 43:65
 desipramine, cortisol, 43:65
 desipramine, MCPP, 43:65
 desipramine, norepinephrine, 43:65
 desipramine, panic disorder, 43:65
 disruptive behavior disorder, aggression, 43:263
 disruptive behavior disorder, childhood disorders, 43:263
 disruptive behavior disorder, cortisol, 43:263
 disruptive behavior disorder, fenfluramine, 43:263
 disruptive behavior disorder, prolactin, 43:263
 fenfluramine, affective disorder, 43:137
 fenfluramine, aggression, 43:263
 fenfluramine, childhood disorders, 43:263
 fenfluramine, cortisol, 43:137, 43:263
 fenfluramine, disruptive behavior disorder, 43:263
 fenfluramine, melancholia, 43:137
 fenfluramine, obsessive-compulsive disorder, 42:81
 fenfluramine, prolactin, 42:81, 43:137, 43:263
 fenfluramine, sex differences, 42:81
 5-HIAA, indole-3-acetic acid, 41:267
 5-HIAA, obsessive-compulsive disorder, 41:267
 5-HIAA, Tourette's syndrome, 41:267
 5-HIAA, tryptamine, 41:267
 imipramine, obsessive-compulsive disorder, 42:41
 imipramine, platelet imipramine binding, 42:41
 imipramine, sulfotransferase in platelets, 42:41
 indole-3-acetic acid, 5-HIAA, 41:267
 indole-3-acetic acid, obsessive-compulsive disorder, 41:267
 indole-3-acetic acid, Tourette's syndrome, 41:267
 indole-3-acetic acid, tryptamine, 41:267
 MCPP, ACTH, 43:1
 MCPP, affective disorder, 43:65
 MCPP, cortisol, 43:65

Serotonin continued

MCPP, desipramine, 43:65
 MCPP, norepinephrine, 43:65
 MCPP, panic disorder, 43:65
 MCPP, prolactin, 43:1
 MCPP, schizophrenia, 43:1
 MCPP, temperature of body, 43:1
 melancholia, affective disorder, 43:137
 melancholia, cortisol, 43:137
 melancholia, fenfluramine, 43:137
 melancholia, prolactin, 43:137
 melatonin, circadian rhythms, 43:161
 melatonin, cortisol, 43:161
 melatonin, platelet serotonin uptake, 43:161
 melatonin, prolactin, 43:161
 memory, catecholamines in urine, 43:277
 memory, MHPG, 43:277
 memory, neuropsychological tasks, 43:277
 memory, Tourette's syndrome, 43:277
 MHPG, catecholamines in urine, 43:277
 MHPG, memory, 43:277
 MHPG, neuropsychological tasks, 43:277
 MHPG, Tourette's syndrome, 43:277
 neuropsychological tasks, catecholamines in urine, 43:277
 neuropsychological tasks, memory, 43:277
 neuropsychological tasks, MHPG, 43:277
 neuropsychological tasks, Tourette's syndrome, 43:277
 norepinephrine, affective disorder, 43:65
 norepinephrine, cortisol, 43:65
 norepinephrine, desipramine, 43:65
 norepinephrine, MCPP, 43:65
 norepinephrine, panic disorder, 43:65
 obsessive-compulsive disorder, fenfluramine, 42:81
 obsessive-compulsive disorder, 5-HIAA, 41:267
 obsessive-compulsive disorder, imipramine, 42:41
 obsessive-compulsive disorder, indole-3-acetic acid, 41:267
 obsessive-compulsive disorder, platelet imipramine binding, 42:41
 obsessive-compulsive disorder, prolactin, 42:81
 obsessive-compulsive disorder, sex differences, 42:81
 obsessive-compulsive disorder, sulfotransferase in platelets, 42:41
 obsessive-compulsive disorder, Tourette's syndrome, 41:267
 obsessive-compulsive disorder, tryptamine, 41:267
 panic disorder, affective disorder, 43:65
 panic disorder, cortisol, 43:65

Serotonin continued

- panic disorder, desipramine, 43:65
- panic disorder, MCPP, 43:65
- panic disorder, norepinephrine, 43:65
- platelet imipramine binding, imipramine, 42:41
- platelet imipramine binding, obsessive-compulsive disorder, 42:41
- platelet imipramine binding, sulfotransferase in platelets, 42:41
- platelet serotonin uptake, circadian rhythms, 43:161
- platelet serotonin uptake, cortisol, 43:161
- platelet serotonin uptake, melatonin, 43:161
- platelet serotonin uptake, prolactin, 43:161
- prolactin, ACTH, 43:1
- prolactin, affective disorder, 43:137
- prolactin, aggression, 43:263
- prolactin, childhood disorders, 43:263
- prolactin, circadian rhythms, 43:161
- prolactin, cortisol, 43:137, 43:161, 43:263
- prolactin, disruptive behavior disorder, 43:263
- prolactin, fenfluramine, 42:81, 43:137, 43:263
- prolactin, MCPP, 43:1
- prolactin, melancholia, 43:137
- prolactin, melatonin, 43:161
- prolactin, obsessive-compulsive disorder, 42:81
- prolactin, platelet serotonin uptake, 43:161
- prolactin, schizophrenia, 43:1
- prolactin, sex differences, 42:81
- prolactin, temperature of body, 43:1
- schizophrenia, ACTH, 43:1
- schizophrenia, MCPP, 43:1
- schizophrenia, prolactin, 43:1
- schizophrenia, temperature of body, 43:1
- sex differences, fenfluramine, 42:81
- sex differences, obsessive-compulsive disorder, 42:81
- sex differences, prolactin, 42:81
- sulfotransferase in platelets, imipramine, 42:41
- sulfotransferase in platelets, obsessive-compulsive disorder, 42:41
- sulfotransferase in platelets, platelet imipramine binding, 42:41
- temperature of body, ACTH, 43:1
- temperature of body, MCPP, 43:1
- temperature of body, prolactin, 43:1
- temperature of body, schizophrenia, 43:1
- Tourette's syndrome, catecholamines in urine, 43:277
- Tourette's syndrome, 5-HIAA, 41:267
- Tourette's syndrome, indole-3-acetic acid, 41:267
- Tourette's syndrome, memory, 43:277

Serotonin continued

- Tourette's syndrome, MHPG, 43:277
- Tourette's syndrome, neuropsychological tasks, 43:277
- Tourette's syndrome, obsessive-compulsive disorder, 41:267
- Tourette's syndrome, tryptamine, 41:267
- tryptamine, 5-HIAA, 41:267
- tryptamine, indole-3-acetic acid, 41:267
- tryptamine, obsessive-compulsive disorder, 41:267
- tryptamine, Tourette's syndrome, 41:267
- Sleep**
- adolescent depression, affective disorder, 41:53
- adolescent depression, childhood depression, 41:53
- adolescent depression, family studies, 41:53
- adolescent depression, polysomnography, 41:53
- affective disorder, adolescent depression, 41:53
- affective disorder, agoraphobia, 44:41
- affective disorder, childhood depression, 41:53
- affective disorder, delta EEG, 41:65
- affective disorder, family studies, 41:53
- affective disorder, longitudinal studies, 42:27
- affective disorder, panic disorder, 44:41
- affective disorder, polysomnography, 41:53, 41:65, 42:13, 42:27, 44:41
- affective disorder, psychotherapy, 42:13, 42:27
- affective disorder, remission, 42:27
- affective disorder, treatment response, 42:13
- agoraphobia, affective disorder, 44:41
- agoraphobia, panic disorder, 44:41
- agoraphobia, polysomnography, 44:41
- bereavement, depressed mood, 43:43
- bereavement, polysomnography, 43:43
- calcium binding protein, chromogranin A, 42:53
- calcium binding protein, polysomnography, 42:53
- calcium binding protein, schizophrenia, 42:53
- childhood depression, adolescent depression, 41:53
- childhood depression, affective disorder, 41:53
- childhood depression, family studies, 41:53
- childhood depression, polysomnography, 41:53
- cholinesterase isozymes, polysomnography, 43:23
- cholinesterase isozymes, schizophrenia, 43:23

Sleep continued

chromogranin A, calcium binding protein, 42:53
 chromogranin A, polysomnography, 42:53
 chromogranin A, schizophrenia, 42:53
 circadian rhythm, growth hormone, 41:155
 circadian rhythm, schizophrenia, 41:155
 delta EEG, affective disorder, 41:65
 delta EEG, polysomnography, 41:65
 depressed mood, bereavement, 43:43
 depressed mood, polysomnography, 43:43
 family studies, adolescent depression, 41:53
 family studies, affective disorder, 41:53
 family studies, childhood depression, 41:53
 family studies, polysomnography, 41:53
 growth hormone, circadian rhythm, 41:155
 growth hormone, schizophrenia, 41:155
 longitudinal studies, affective disorder, 42:27
 longitudinal studies, polysomnography, 42:27
 longitudinal studies, psychotherapy, 42:27
 longitudinal studies, remission, 42:27
 panic disorder, affective disorder, 44:41
 panic disorder, agoraphobia, 44:41
 panic disorder, polysomnography, 44:41
 polysomnography, adolescent depression, 41:53
 polysomnography, affective disorder, 41:53, 41:65, 42:13, 42:27, 44:41
 polysomnography, agoraphobia, 44:41
 polysomnography, bereavement, 43:43
 polysomnography, calcium binding protein, 42:53
 polysomnography, childhood depression, 41:53
 polysomnography, cholinesterase isozymes, 43:23
 polysomnography, chromogranin A, 42:53
 polysomnography, delta EEG, 41:65
 polysomnography, depressed mood, 43:43
 polysomnography, family studies, 41:53
 polysomnography, longitudinal studies, 42:27
 polysomnography, panic disorder, 44:41
 polysomnography, psychotherapy, 42:13, 42:27
 polysomnography, remission, 42:27
 polysomnography, schizophrenia, 42:53, 43:23
 polysomnography, treatment response, 42:13
 psychotherapy, affective disorder, 42:13, 42:27
 psychotherapy, longitudinal studies, 42:27
 psychotherapy, polysomnography, 42:13, 42:27
 psychotherapy, remission, 42:27
 psychotherapy, treatment response, 42:13
 remission, affective disorder, 42:27
 remission, longitudinal studies, 42:27
 remission, polysomnography, 42:27

Sleep continued

remission, psychotherapy, 42:27
 schizophrenia, calcium binding protein, 42:53
 schizophrenia, cholinesterase isozymes, 43:23
 schizophrenia, chromogranin A, 42:53
 schizophrenia, circadian rhythm, 41:155
 schizophrenia, growth hormone, 41:155
 schizophrenia, polysomnography, 42:53, 43:23
 treatment response, affective disorder, 42:13
 treatment response, polysomnography, 42:13
 treatment response, psychotherapy, 42:13
Stroop task
 color naming, frontal lobe, 41:137
 color naming, neuropsychological tests, 41:137
 color naming, schizophrenia, 41:137
 frontal lobe, color naming, 41:137
 frontal lobe, neuropsychological tests, 41:137
 frontal lobe, schizophrenia, 41:137
 neuropsychological tests, color naming, 41:137
 neuropsychological tests, frontal lobe, 41:137
 neuropsychological tests, schizophrenia, 41:137
 schizophrenia, color naming, 41:137
 schizophrenia, frontal lobe, 41:137
 schizophrenia, neuropsychological tests, 41:137
Substance abuse
 abstinence, carbidopa treatment, 43:77
 abstinence, cocaine, 43:77
 abstinence, growth hormone, 43:77
 abstinence, homovanillic acid, 43:77
 abstinence, MHPG, 43:77
 abstinence, prolactin, 43:77
 carbidopa treatment, abstinence, 43:77
 carbidopa treatment, cocaine, 43:77
 carbidopa treatment, growth hormone, 43:77
 carbidopa treatment, homovanillic acid, 43:77
 carbidopa treatment, MHPG, 43:77
 carbidopa treatment, prolactin, 43:77
 cocaine, abstinence, 43:77
 cocaine, carbidopa treatment, 43:77
 cocaine, growth hormone, 43:77
 cocaine, homovanillic acid, 43:77
 cocaine, MHPG, 43:77
 cocaine, prolactin, 43:77
 growth hormone, abstinence, 43:77
 growth hormone, carbidopa treatment, 43:77
 growth hormone, cocaine, 43:77
 growth hormone, homovanillic acid, 43:77
 growth hormone, MHPG, 43:77
 growth hormone, prolactin, 43:77
 HIV, neuropsychological tests, 41:163
 homovanillic acid, abstinence, 43:77
 homovanillic acid, carbidopa treatment, 43:77
 homovanillic acid, cocaine, 43:77

Substance abuse continued

homovanillic acid, growth hormone, 43:77

homovanillic acid, MHPG, 43:77

homovanillic acid, prolactin, 43:77

MHPG, abstinence, 43:77

MHPG, carbidopa treatment, 43:77

MHPG, cocaine, 43:77

MHPG, growth hormone, 43:77

MHPG, homovanillic acid, 43:77

MHPG, prolactin, 43:77

neuropsychological tests, HIV, 41:163

prolactin, abstinence, 43:77

prolactin, carbidopa treatment, 43:77

prolactin, cocaine, 43:77

prolactin, growth hormone, 43:77

prolactin, homovanillic acid, 43:77

prolactin, MHPG, 43:77

Symptom Checklist-90

obsessive-compulsive disorder, reliability and validity, 41:37

reliability and validity, obsessive-compulsive disorder, 41:37

Terguride

neuroleptics, Parkinsonism, 41:9

neuroleptics, schizophrenia, 41:9

neuroleptics, side effects, 41:9

Parkinsonism, neuroleptics, 41:9

Parkinsonism, schizophrenia, 41:9

schizophrenia, neuroleptics, 41:9

schizophrenia, Parkinsonism, 41:9

schizophrenia, side effects, 41:9

side effects, neuroleptics, 41:9

side effects, schizophrenia, 41:9

Tourette's syndrome

catecholamines in urine, memory, 43:277

catecholamines in urine, MHPG, 43:277

catecholamines in urine, neuropsychological tasks, 43:277

catecholamines in urine, serotonin, 43:277

5-HIAA, indole-3-acetic acid, 41:267

5-HIAA, obsessive-compulsive disorder, 41:267

5-HIAA, serotonin, 41:267

5-HIAA, tryptamine, 41:267

homovanillic acid, neuropsychological tasks, 43:277

homovanillic acid, trace amines, 43:277

indole-3-acetic acid, 5-HIAA, 41:267

indole-3-acetic acid, obsessive-compulsive disorder, 41:267

indole-3-acetic acid, serotonin, 41:267

indole-3-acetic acid, tryptamine, 41:267

memory, catecholamines in urine, 43:277

memory, MHPG, 43:277

memory, neuropsychological tasks, 43:277

Tourette's syndrome continued

memory, serotonin, 43:277

MHPG, catecholamines in urine, 43:277

MHPG, memory, 43:277

MHPG, neuropsychological tasks, 43:277

MHPG, serotonin, 43:277

neuropsychological tasks, catecholamines in urine, 43:277

neuropsychological tasks, homovanillic acid, 43:277

neuropsychological tasks, memory, 43:277

neuropsychological tasks, MHPG, 43:277

neuropsychological tasks, serotonin, 43:277

neuropsychological tasks, trace amines, 43:277

obsessive-compulsive disorder, 5-HIAA, 41:267

obsessive-compulsive disorder, indole-3-acetic acid, 41:267

obsessive-compulsive disorder, serotonin, 41:267

obsessive-compulsive disorder, tryptamine, 41:267

serotonin, catecholamines in urine, 43:277

serotonin, 5-HIAA, 41:267

serotonin, indole-3-acetic acid, 41:267

serotonin, memory, 43:277

serotonin, MHPG, 43:277

serotonin, neuropsychological tasks, 43:277

serotonin, obsessive-compulsive disorder, 41:267

serotonin, tryptamine, 41:267

trace amines, homovanillic acid, 43:277

trace amines, neuropsychological tasks, 43:277

tryptamine, 5-HIAA, 41:267

tryptamine, indole-3-acetic acid, 41:267

tryptamine, obsessive-compulsive disorder, 41:267

tryptamine, serotonin, 41:267

Tridimensional Personality Questionnaire

affective disorder, manic symptoms, 41:215

affective disorder, psychotic symptoms, 41:215

manic symptoms, affective disorder, 41:215

manic symptoms, psychotic symptoms, 41:215

psychotic symptoms, affective disorder, 41:215

Tryptophan

psychotic symptoms, manic symptoms, 41:215

5-HIAA, indole-3-acetic acid, 41:267

5-HIAA, obsessive-compulsive disorder, 41:267

5-HIAA, serotonin, 41:267

5-HIAA, Tourette's syndrome, 41:267

indole-3-acetic acid, 5-HIAA, 41:267

indole-3-acetic acid, obsessive-compulsive disorder, 41:267

Tryptophan continued

indole-3-acetic acid, serotonin, 41:267

indole-3-acetic acid, Tourette's syndrome, 41:267

obsessive-compulsive disorder, 5-HIAA, 41:267

obsessive-compulsive disorder, indole-3-acetic acid, 41:267

obsessive-compulsive disorder, serotonin, 41:267

obsessive-compulsive disorder, Tourette's syndrome, 41:267

serotonin, 5-HIAA, 41:267

serotonin, indole-3-acetic acid, 41:267

serotonin, obsessive-compulsive disorder, 41:267

serotonin, Tourette's syndrome, 41:267

Tourette's syndrome, 5-HIAA, 41:267

Tourette's syndrome, indole-3-acetic acid, 41:267

Tryptophan continued

Tourette's syndrome, obsessive-compulsive disorder, 41:267

Tourette's syndrome, serotonin, 41:267

Vagal tone

diazepam, heart rate, 41:89

diazepam, norepinephrine, 41:89

diazepam, normal men, 41:89

heart rate, diazepam, 41:89

heart rate, norepinephrine, 41:89

heart rate, normal men, 41:89

norepinephrine, diazepam, 41:89

norepinephrine, heart rate, 41:89

norepinephrine, normal men, 41:89

normal men, diazepam, 41:89

normal men, heart rate, 41:89

normal men, norepinephrine, 41:89

